

UC Irvine

UC Irvine Previously Published Works

Title

Plant-Dominant Low-Protein Diet for Conservative Management of Chronic Kidney Disease

Permalink

<https://escholarship.org/uc/item/604527r7>

Authors

Kalantar-Zadeh, Kamyar
Joshi, Shivam
Schlueter, Rebecca
[et al.](#)

Publication Date

2020

DOI

10.20944/preprints202005.0516.v1

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

Title:

Plant-Dominant Low-Protein Diet for Conservative Management of Chronic Kidney Disease

(Running Head: Plant-Dominant Diet in CKD)

Authors:

**Kamyar Kalantar-Zadeh, MD, MPH, PhD^{1,2}; Shivam Joshi, MD³;
Rebecca Schlueter, RD⁴; Joanne Cooke, MS, RD⁵; Amanda Brown-Tortorici, RD,
PhD¹; Meghan Donnelly, RD⁶; Sherry Schulman, MS, RD, MBA⁷; Wei-Ling Lau,
MD¹;
Connie M Rhee, MD, MSc¹; Elani Streja, MPH, PhD^{1,2}; Ekamol Tantisattamo, MD,
MPH¹; Antony Ferrey, MD¹; Ramy S Hanna; MD¹; Joline L Chen, MD, MSc²;
Shaista Malik, MD⁷; Danh V Nguyen, MS, PhD¹; Susan T Crowley, MD, MBA^{8,9};
and
Csaba P. Kovesdy, MD¹⁰**

Affiliations:

(1) University of California Irvine (UCI), Department of Medicine, Division of Nephrology Hypertension and Kidney Transplantation, Orange, CA, USA

(2) Tibor Rubin VA Long Beach Healthcare System, Long Beach, CA, USA

(3) Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA

- (4) Lexington VA Healthcare System, Lexington, KY, USA
- (5) Kansas City VA Medical Center, Kansas City, MO, USA
- (6) Flavis/Dr. Schar USA, Inc., Lyndhurst, NJ, USA
- (7) UCI Health Susan Samueli Center Integrative Health Institute, Irvine, CA, USA
- (8) VA Connecticut Healthcare System, West Haven, CT
- (9) Division of Nephrology, Yale University School of Medicine, New Haven, CT
- (10) Division of Nephrology, University of Tennessee Health Sciences Center, Memphis, TN, USA

Correspondence:

Kamyar Kalantar-Zadeh, MD, MPH, PhD

Division of Nephrology, Hypertension and Kidney Transplantation

University of California Irvine, School of Medicine, Orange, CA

Tel: 714-456-5142

E-mail: kkz@uci.edu

Word and Display Count:

Words: 5,721 words

Abstract: 250 words

Displays: 4 Figures and 5 Tables

References: 145

Funding Sources (optional):

This work was partially supported by KKZ's research grants from the National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Disease grant K24-DK091419.

Acknowledgement:

The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the Journal.

Potential Conflict of Interests:

Dr. K. Kalantar-Zadeh has received honoraria and/or support from Abbott, Abbvie, ACI Clinical (Cara Therapeutics), Akebia, Alexion, Amgen, Ardelyx, ASN (American Society of Nephrology), Astra-Zeneca, Aveo, BBraun, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hofstra Medical School, IFKF (International Federation of Kidney Foundations), ISH (International Society of Hemodialysis), International Society of Renal Nutrition & Metabolism (ISRNM), JSDT (Japanese Society of Dialysis Therapy), Hospira, Kabi, Keryx, Kissei, Novartis, OPKO, NIH (National Institutes of Health), NKF (National Kidney Foundations), Pfizer, Regulus, Relypsa, Resverlogix, Dr Schaer, Sandoz, Sanofi, Shire, VA (Veterans' Affairs), Vifor, UpToDate, ZS-Pharma.

No relevant sources of conflict of interest have been declared by other authors.

ABSTRACT

Chronic kidney disease (CKD) affects >10% of the adult population. Each year approximately 120,000 Americans develop end-stage kidney disease and initiate dialysis, which is costly and associated with functional impairments, worse health-related quality of life, and high early-mortality rates exceeding 20% in the first year. Recent declarations by the World Kidney Day and the U.S. Government Executive Order seek to implement strategies that reduce the burden of kidney failure by slowing CKD progression and controlling uremia without dialysis. Pragmatic dietary interventions may have a role in improving CKD outcomes and preventing or delaying dialysis initiation. Evidence suggests that a patient-centered plant-dominant low-protein diet (PLADO) of 0.6-0.8 g/kg/day comprised of >50% plant-based sources, administered by dietitians trained in non-dialysis CKD care, can be promising. The scientific premise of the PLADO is based on the observations that high protein diets with high meat intake are not only associated with higher cardiovascular disease risk but also higher CKD incidence and faster CKD progression due to increased intraglomerular pressure and glomerular hyperfiltration. Meat intake increases production of nitrogenous end-products, worsens uremia, and may increase the risk of hyperkalemia, given constipation from the typical low fiber intake. Plant-dominant, fiber-rich, low-protein diet may lead to favorable alterations in the gut microbiome, which can modulate uremic toxin generation and slow CKD progression, along with reducing cardiovascular risk in CKD patients. PLADO is a heart-healthy, safe, flexible, and feasible diet that could be the centerpiece of a conservative and preservative CKD-management strategy that challenges the prevailing dialysis-centered paradigm.

Keywords: Plant-dominant, low-protein, dietary protein intake, glomerular hyperfiltration.

The Burden of Chronic Kidney Disease

Chronic kidney disease (CKD) has no cure and affects more than 10% of the adult population throughout the world.¹ If persons with CKD survive long enough, many will inevitably reach kidney failure, also known as end-stage kidney disease (ESKD), which is not compatible with life without kidney replacement therapy in the form of maintenance dialysis treatment or kidney transplantation.¹⁻⁴ However, ESKD patients who transition to dialysis often have poor clinical outcomes. Cardiovascular morbidity and mortality of CKD are exceptionally high with an overall 5-year survival less than 50%.^{5,6} In the United States (US), total Medicare and Veterans Administrations (VA) spending for CKD continues to increase.⁴ Each year approximately 120,000 Americans develop ESKD and initiate dialysis,⁵ including 12,000 U.S. Veterans.⁵⁻⁸ Despite the purported life-prolonging effects of dialysis,⁹ 10% of these patients die in the first 90 days after dialysis transition and >20% in the first year.⁶ In addition to the high rates of early dialysis mortality, a large proportion of elderly patients experience major functional decline after transition to dialysis therapy.¹⁰ Hence, delaying or preventing kidney failure to avoid kidney replacement therapy may improve clinical outcomes while averting the high costs of dialysis therapy and preserving limited resources.

The World Kidney Day steering committee declared 2020 and 2021 as the years of CKD prevention and living well with CKD, respectively. These declarations underscore the paramount importance of both primary CKD prevention as well as secondary and tertiary interventions for early diagnosis of CKD and treatment to control progression to ESKD and its complications, respectively.^{1,11} Among the core components of the preventative strategies are nutritional and dietary intervention as featured in this

review article. Moreover, in July 2019, an unprecedented Executive Order by the U.S. President, known as the “Advancing American Kidney Health Initiative” sought to reduce the number of Americans developing kidney failure by 25% by 2030 through improved efforts to slow the progression of CKD.¹² This timely executive order underscores the importance of preventive CKD measures and reiterates the critical, yet underappreciated role of leveraging dietary interventions in optimizing kidney health.¹² This review article highlights past and contemporary data on the dietary management of CKD with focus on the role of plant-based, restricted protein diets based on the premise that feasible dietary approaches should be the cornerstone of non-pharmacologic strategies in slowing CKD progression and avoiding or delaying ESKD.¹³

High Protein Diets May Be Harmful to Kidney Health

While the U.S. National Academy of Medicine has maintained that *Recommended Dietary Allowance* (RDA) of dietary protein intake (DPI) should be 0.8 grams per kilogram of the ideal body weight per day (g/kg/day), Americans on average consume much higher amounts of protein, i.e., 1.2 to 1.4 g/kg/day, mostly from animal sources, according to analyses from the National Health and Nutrition Examination Survey (NHANES).¹⁴ In recent practice, higher DPI has been recommended to combat obesity and diabetes,^{15, 16} despite recent data suggesting higher risk of CKD incidence and progression with higher DPI, especially from red meat.¹⁷⁻¹⁹ Keto-diets, which are also high in protein and animal fats, are gaining popularity across different healthcare systems throughout the world as a recommended dietary intervention for adults with diabetes.²⁰ Despite its immediate appeal for the use of type 2 diabetes, the ketogenic diet has not

been as effective for glycemic control or weight loss in randomized, controlled trials as often touted and may carry additional risks to long-term health.²¹ Further, previous and emerging data (Table 1) suggest that high DPI in these diets, by way of causing increased intra-glomerular pressure with resultant glomerular hyperfiltration, may adversely affect kidney health over time across populations with or at-risk for CKD.¹⁷

A Low Protein Diet Preserves Kidney Function

A low protein diet (LPD), defined as DPI 0.6-0.8 g/kg/day, has consistently been shown to lower intra-glomerular pressure (Figure 1).²² This effect, if exerted consistently, may preserve long-term kidney function as corroborated in both animal models and in human studies of CKD, including several meta-analyses.²³⁻²⁷ The scientific premise for these DPI targets was presented in a recent critical review and meta-analysis of 16 dietary trials with more than 30 CKD patients in each trial (Figure 2),²⁶ and also discussed in a 2017 *New England Journal of Medicine* review paper.²² These data highlight the utility of LPD for the management of CKD (Table 2), suggesting that a LPD of 0.6-0.8 g/kg/day vs. higher amounts is associated with lower ESKD risk, higher serum bicarbonate and lower serum phosphorus levels, less azotemia, and lower mortality trends.²⁶ Whereas we and others have recommended DPI of 0.6-0.8 g/kg/day, some other investigators including Metzger et al.²⁸ showed that a DPI of <0.6 g/kg/day may result in even slower CKD progression; however, a DPI of 0.6-0.8 g/kg/day is considered the most pragmatic and safest target when used without amino-acid or keto-analogue supplements to avoid *protein-energy wasting* (PEW). For persons without established CKD but who are at high risk of CKD, such as those with a solitary kidney or diabetic glomerular hyperfiltration, it is recommended that a high dietary protein intake >1.0 g/kg/day should be avoided.²⁹

especially since patients with diabetes develop more severe hyperfiltration in response to high DPI.⁵⁰

Evidence suggests that safety and adherence to a LPD is equivalent to a normal protein diet and that there is no risk of the malnutrition or PEW that might occur with very-low protein diets (DPI 0.3-0.6 g/kg/day), even sans supplementation with essential amino acids or their keto-analogues.²⁶ However, while most studies suggest that a LPD ameliorates CKD progression, there are also some mixed findings,^{31, 32} including the primary analyses of the Modification of Diet in Renal Disease (MDRD) Study. Most trials except for the MDRD were small, used surrogate endpoints, were considered less rigorous compared to MDRD, used dietary interventions that were labor-intensive, were not patient-centered, and not aligned with contemporary culture of more plant-based sources. Due to the impractical aspects of prior LPD regimens, and in part to the marginal effects of a LPD in the MDRD, which did not achieve statistical significance, LPD has not been adopted in most CKD clinics. Thus, there remains an unmet need for more contemporary, well-powered, pragmatic randomized controlled trials that apply LPD as a convenient and patient-centered intervention, especially with a newer focus on plant-dominant diet regimens.

Plant-Based Foods Have a Favorable Impact on Kidney Health

The typical American diet contains 15%-20% protein with less than one-third of protein sources from plants.³³ While human trials on the effects of high protein intake have yield mixed findings, animal models are relatively consistent with evidence of histological damage including a 60–70% increase in renal and glomerular volumes, 55%

more fibrosis and 30% more glomerulosclerosis.³⁴ A recent comprehensive and critical review of the literature concluded that daily red meat consumption over years may increase CKD risk, whereas fruit and vegetable proteins may be renal protective.¹⁸ Prior studies summarized by some of the authors of this article^{29, 31, 32, 35-37} and others³⁸⁻⁴¹ suggest that animal-based protein is harmful to kidney health, while a plant-dominant diet may slow CKD progression. A landmark study was presented by Kontessis et al.⁴² who studied volunteers fed for 3 weeks with a vegetable-based diet (N=10), an animal protein diet (N=10), or an animal protein diet supplemented with fiber (N=7), all with the same amount of total protein; animal-based protein diets increased GFR more than similar amounts of plant-based proteins, i.e., higher glomerular hyperfiltration was observed with more meat and less vegetable-derived proteins.⁴² Other important studies supporting the benefit of a plant-dominant diet in slowing CKD progression include the study by Lin et al.⁴³ (examined 3,348 women in the Nurses' Health Study and found that the highest quartile of meat intake was associated with 72% higher risk of microalbuminuria), Kim et al.⁴⁴ (showed that in 14,686 middle-aged adults, higher adherence to a plant-based diet was associated with favorable kidney outcomes), Haring et al.⁴⁵ (showed that red and processed meat were associated with higher CKD risk, while nuts, low-fat dairy products, and legumes were protective against the development of CKD) and Chen et al.⁴⁶ (showed lower mortality in CKD patients on diet with higher plant sources).

Benefits of a Plant-Dominant Low Protein Diet

We define a plant-dominant LPD, also referred to as PLADO, as a type of LPD with DPI of 0.6-0.8 g/kg/day with at least 50% plant-based sources to meet the targeted

dietary protein, and which should preferably be whole, unrefined, and unprocessed foods (**Figure 3**). This is consistent with the RDA of DPI of 0.8 g/kg/day, which has a high safety margin, given that based on established metabolic studies¹³ the lowest DPI requirement to avoid catabolic changes is 0.45 to 0.5 g/kg/day. It has been suggested that $\geq 50\%$ of DPI should be of “high biologic value” with high gastrointestinal absorbability to ensure adequate intake of essential amino acids.³ However, other metrics including the “protein digestibility-corrected amino-acid score”, which is a more accurate method recommended by the Food and Agricultural Organization and the World Health Organization, grant high scores to many plant-based sources and may be a more appropriate measure of protein quality.⁴⁷ Other features of PLADO include relatively low sodium intake < 3 g/day, higher dietary fiber of at least 25-30 g/day, and adequate dietary energy intake (DEI) of 30-35 Cal/kg/day, assuming that the DEI calculations are based on the ideal body weight, similar to the approach to calculating DPI (**Figure 3**).

There are multiple pathways by which a LPD with at least 50% plant-based protein sources ameliorates CKD progression, in addition to reducing glomerular hyperfiltration³¹ (**Table 3**):

(1) Reduction in nitrogenous compounds leads to less production of ammonia and uremic toxins as an effective strategy in controlling uremia and delaying dialysis initiation.²⁶

(2) Synergism with RAAS and SGLT2 inhibitors, since LPD reinforces the pharmaco-therapeutic effect of lowering intra-glomerular pressure through complementary mechanisms (**Figure 1**).⁴⁸

(3) Attenuation of metabolites derived from gut bacteria that are linked with CKD and CV disease: Animal protein ingredients including choline and carnitine are converted by gut flora into trimethylamine (TMA) and TMA N-oxide (TMAO) that are associated with atherosclerosis, renal fibrosis⁴⁹, and increased risk of CV disease and death.⁵⁰ The favorable impact on the gut microbiome⁵¹ similarly leads to lower levels of other uremic toxins such as indoxyl sulfate and p-cresol sulfate.⁵²

(4) Decreased acid load: Plant foods have a lower acidogenicity in contrast to animal foods, and this alkalization may have additional effects beyond mere intake of natural alkali.⁵³

(5) Reduced phosphorus burden: There is less absorbable phosphorus in plant-based proteins given the presence of indigestible phytate binding to plant-based phosphorus. Fruits and vegetables are less likely to have added phosphorus-based preservatives that are often used for meat processing.^{59, 54-56}

(6) Modulation of advanced glycation end products (AGE's): Higher dietary fiber intake results in a favorable modulation of AGE⁵⁷ which can slow CKD progression,⁵⁸ enhance GI motility and lower the likelihood of constipation that is a likely contributor to hyperkalemia.

(7) Favorable effects on potassium metabolism: A plant-based diet based on more whole fruits and vegetables lessens the likelihood of potassium-based additives that are often found in meat products.^{59, 60}

(8) Anti-inflammatory and anti-oxidant effects: There is a decreased risk of CKD progression and CV disease due to higher intake of natural anti-inflammatory and antioxidant ingredients including carotenoids, tocopherols, and ascorbic acid.^{61, 62}

Features of PLADO Regimens

As stated above, the plant-dominant restricted protein diet consists of an LPD amounting to 0.6-0.8 g/kg/day with at least 50% of the dietary protein being from plant-based sources. [Table 4](#) compares PLADO with a standard diet in the USA, in that the total amount and proportion of plant-based protein is usually 1.2-1.4 g/kg/day and 20-30%, respectively, whereas the PLADO not only has less total protein of 0.6-0.8 g/kg/day but it also includes 50% to 70% of plant-based sources for this restricted DPI goal. Hence, an 80 kg person with CKD, for instance, would be recommended to have 46 to 64 grams of DPI per day, out of which 24 to 45 grams will be from plant-based sources, while the rest is according to patient choice and preferences. As shown in [Table 4](#), the total amount of animal-based protein under PLADO regimen is 14 to 32 g/day, which is less than half of the 68 to 83 g/day in the standard diet, but the patient also has the choice of being nearly or totally plant-based. There are different types of vegetarian diets:³¹ (1) Vegan, or strict vegetarian (100% plant-based), diets that not only exclude meat, poultry, and seafood but also eggs and dairy products; (2) Lacto- and/or ovo-vegetarian diets that may include dairy products and/or eggs; (3) Pesco-vegetarian diets that include a vegetarian diet combined with occasional intake of some or all types of sea-foods, mostly fish; and (4) Flexitarians, which is mostly vegetarian of any of the above types with occasional inclusion of meat.³¹ The PLADO does NOT require adherence to any of these strict diets, but is a flexible LPD of 0.6-0.8 g/kg/day range with 50% or more plant-based sources of protein based on the patient's choice ([Table 4](#)). Whereas some nephrologists may promote a pesco-lacto-ovo-vegetarian LPD with >50% plant sources, patients have

the ultimate discretion to decide about the non-plant-based portion of the protein ad lib. Based on our decades-old experience in running LPD clinics, most CKD patients will adhere to 50-70% plant-based sources, while some may choose >70% or strictly plant-based diets.

We recommend a daily sodium intake <3 g/day for a more pragmatic approach,²² as opposed to the American Heart Association's suggested <2.3 g/day given the lack of strong evidence for the latter.²² The PLADO regimen is CKD-patient-centric and flexible with respect to the targeted dietary goals, and is constructed based on the preferences of the patient as opposed to strict dietary regimens, with the dietitian working with patients and their care-partners to that end. Whereas we recommend a moderately low sodium intake of <3 g/day under the PLADO regimen, in those without peripheral edema and well-controlled hypertension, we have allowed slightly higher sodium intake but not greater than 4 g/day given that recent large cohort studies showed poor CKD outcomes with daily urinary sodium excretion >4 g/day.⁶³ (Figure 3).

Safety and Adequacy of a Plant-Dominant Low-Protein Diet

Potential challenges of PLADO are outlined in [Table 3](#), which will be largely related to the adequacy and safety of this type of dietary management of CKD patients. The risks of PEW and sarcopenia are the leading concerns, although there is little evidence for these sequelae. As discussed above and based on the U.S. recommended RDA for safe DPI ranges, it is highly unlikely that the targeted DPI of 0.6-0.8 g/kg/day with >50% plant sources will engender PEW in clinically stable individuals. No PEW was reported in 16 LPD trials cited above,^{13, 26} including the MDRD trial,¹³ although

PEW per se is a risk of poor CKD outcomes including faster CKD progression.⁶⁴ However, it is prudent that in patients who may develop signs of PEW or acute kidney injury (AKI), higher DPI targets should be temporarily used until PEW or AKI is resolved. On the other hand, if there is concern related to the likelihood of obesity and hyperglycemia, patients and providers should be reassured that LPD therapy in CKD has not been shown to be associated with such risks, and indeed a LPD with plant-based sources has salutary effects on insulin resistance and glycemic index, as long as total calorie intake remains within the targeted range of 30-35 kcal/kg/day.^{32, 35}

Another frequently stated concern is the perceived risk of hyperkalemia. We are not aware of scientific evidence to support the cultural dogma that dietary potassium restriction in CKD improves outcomes.⁶⁵ Evidence suggests that dietary potassium, particularly from whole, plant-based foods, does not correlate closely with serum potassium variability.^{66, 67} Indeed, a high-fiber diet enhances bowel motility and likely prevents higher potassium absorption, and alkalization with plant-based dietary sources also lowers risk of hyperkalemia.⁶⁸⁻⁷² Of note, dried-fruit, juices, smoothies and sauces of fruits and vegetables require additional consideration given their high potassium concentrations. Moreover, newly available potassium-binders, which were not FDA-approved during the era of prior LPD trials such as the MDRD, may be used in the contemporary management of CKD patients at the discretion of clinicians.⁷³

Diet palatability and adherence to LPD or meatless diets are often cited as dietary management challenges. Based on our extensive experience in running patient-centered LPD clinics for hundreds of CKD patients,³ and given prior data on dietary adherence research^{3, 74} the suggested PLADO with DPI of 0.6-0.8 g/kg/day and >50% plant-based

sources is feasible and well-accepted among patients with CKD.³ Patients have the opportunity to choose the contribution of protein plant sources between 50% to 75% or >75%, and these two strata along with palatability, appetite,⁷⁵ and adherence should be monitored closely in CKD clinics. If there is concern about inadequate fish intake, given data on the benefits of higher fish intake including fish oil in CKD,⁷⁶⁻⁷⁸ treated CKD patients can be reminded of the opportunity to consume more fish products for their remaining non-plant sources of the dietary protein. Likewise, concerns about B12 deficiency associated with meatless diets can be mitigated by the use of oral supplements as needed.⁷⁹

Impact of PLADO on Microbiome in CKD

Eating a plant-dominant, fiber-rich LPD may lead to favorable alterations in the gut microbiome, which can modulate uremic toxin generation and slow CKD progression, along with reducing cardiovascular risk in CKD patients.^{22, 80-82} Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium.⁸³ The influx of retained uremic solutes from the bloodstream per se induces changes in the microbial population simultaneous with gut wall inflammation and breakdown of epithelial junctions.⁸⁴⁻⁹⁵ Bacterial-derived toxins then translocate back across the leaky gut barrier into the systemic circulation and promote inflammation and multi-organ dysfunction.^{84, 96} At least five major gut-derived uremic toxins have been associated with cardiovascular disease and mortality in CKD: indoxyl sulfate, indole-3 acetic acid, p-cresyl sulfate, TMAO, and phenylacetylglutamine.⁹⁶ In a small study that included 9 CKD patients per group, and which had a short duration of 6 months, LPD with or without inulin prebiotic supplementation was reported to modify the gut

microbiome, increase serum bicarbonate, and improve physical function scores,⁹⁷ but the investigators did not examine CKD progression or levels of gut-derived uremic toxins. Future studies should examine the role of PLADO regimens on gut microbiome in CKD patients.

Similarities and Distinctions between PLADO and other CKD Diets

In contrast to other diets used for the management of CKD, the PLADO offers a more pragmatic and patient-centered nutritional management which is aligned with contemporary dietary management goals. Unlike the diets used in the MDRD study and other studies that focused on hard outcomes, the premise of PLADO is based on its expected effects on both hard endpoints and patient-centered outcomes, including health-related quality of life, uremic symptoms, and diet palatability, while safety and adequacy remain among important goals. It is important to note that the MDRD Study was conducted in the early 1990's under dietary practices that are not relevant to contemporary practice. While high-protein diets such as keto, Atkins, and Paleo diets are popular in contemporary culture, there has been growing interest in plant-based diets across the lay and scientific communities and professional societies including the National Kidney Foundation,⁹⁸ which were not considered in the MDRD Study.

Restricted protein diets that are partially to entirely plant-based are more broadly generalizable to the adult populations as compared to the prior LPD trials, including the MDRD study. PLADO can be safely recommended to both patients with early CKD, including those with any degree of proteinuria regardless of etiology,⁹⁹ as well as to late-stage CKD populations, including those with an eGFR <45 ml/min/1.73m², without a

lower eGFR limit, to take advantage of the effects of LPDs in controlling uremia and averting the need for dialysis. This stands in sharp contrast to the MDRD study, whose participants had relatively high eGFRs (eGFR 25 to 55 ml/min/1.73m²), and which focused on slowing the progression of moderate CKD. Indeed, in the MDRD study, patients did not have diabetes,¹⁰⁰ whereas PLADO can be non-differentially prescribed to both patients with and without diabetes with any degree of severity of CKD, consistent with the broader unmet need in the adult CKD population. It is important to note that polycystic kidney disease (PKD) patients, who usually have slower CKD progression rates, comprised 24% of the MDRD study participants.¹⁰⁰

Role of Dietitians in PLADO

The successful implementation of plant-based restricted protein diets is dependent on the engagement of dietitians who are well trained in the field of non-dialysis CKD.¹⁰¹ Dietitians should assess regularly the dietary protein and energy as well as micronutrient intakes of CKD patients by both periodic dietary assessments and 24-hour urine collections to estimate dietary intakes of macro- and micronutrients and to evaluate and improve adherence to dietary recommendations (**Figure 4**).²² Behavior change counseling by dietitians is a key skill set that is critical in successful lifestyle and habit modifications. Easy-to-use telehealth alternatives are important to overcome existing and emerging challenges in dietetic education including under the COVID-19 pandemic and other restrictions, so that patients are provided with pragmatic tools and comprehensible and consistent dietary information and skills, which fosters ownership and self-monitoring in kidney health management such as healthy kitchen approaches.^{102,103}

Unfortunately, however, an overwhelming majority of CKD patients never meet with a CKD-specialized dietitian prior to dialysis initiation, and most patients remain uninformed about the role of diet in disease progression and management. Among clinicians and patients, lack of awareness about the benefits of plant-dominant, low protein dietary interventions (other than low potassium diets) and available insurance reimbursement for medical nutrition therapy under guidance of a registered dietitian are significant barriers. In many regions especially in North America and Europe, the focus and expertise of the dietitians have traditionally been centered on dialysis patient care as opposed to preventative non-dialysis dependent CKD. Past and recent reports suggest under-utilization of dietetic manpower and expertise for the purpose of non-dialysis CKD care.⁸ A collective groundswell of events has recently occurred which aim to improve CKD care: the World Kidney Day focuses on reduction of the onset and progression of CKD through primary, secondary and tertiary measures;⁹ the U.S. Presidential Executive Order, “Advancing American Kidney Health”,¹² refocuses kidney care from dialysis incentives to avoidance of kidney failure; the US Veterans Health Administration issued Directive 1053, “Chronic Kidney Disease: Prevention, Early Recognition, and Management”, establishing federal policy targeting CKD prevention through integrated care including medical nutrition therapy,¹⁰⁴ and, the advocacy of renal dietitians for patient-centric LPD regimens containing fewer animal products and more plant-based sources of protein such as PLADO.¹⁰⁵ This is a sharp contrast to prior LPD recommendations with less flexible regimens such as strict plant-based dieting or very low DPI of <0.4 g/kg/day combined with supplements, that may be less palatable,

unsustainable, and non-pragmatic for broad application in the real-world scenarios of CKD patient care.

Recommendations for Practical Implementation of PLADO

After the first 3 months, which includes preliminary education on LPD regimens with >50% plant sources and acquiring food preparation skills, participating CKD patients should be assessed every 3 to 6 months by the dietitian. During each visit, dietary re-education along with dietary assessment should be conducted and patient's progress in reaching the goals should be examined. In line with the pragmatic nature of PLADO regimens, the dietary re-education and follow-up visits can be performed in parallel with routine follow-up CKD clinic visits on the same days of the ambulatory clinic appointments, thus avoiding the burden of additional diet-related travels to the CKD clinic. In addition to in-person visits, there could be monthly to tri-monthly telephone calls with the CKD patients under CKD therapy, or even more frequently if needed, to reinforce diet planning and adherence and to answer questions about preparation of plant-dominant meals and cooking questions. Adherence to PLADO should be evaluated by comparing the LPD goals, i.e., 0.6-0.8 g/kg/day and >50% plant sources, to the estimated DPI using 24-hr urine nitrogen (see below) and 3-day diet assessments, respectively. Complementary dietary education of the patients and their care-partners should be provided both during the face-to-face visits and via phone calls.

The specialized knowledge and services of a renal dietitian ensure accurate nutrition education, meal planning and evaluation of body composition to sustain health. Components of a CKD nutrition evaluation may include the following (see [Table 5](#)): (1)

Dietary education for LPD with >50% plant-based protein sources, (2) Dietary assessment using a 3-day diet diary with interview, (3) Simplified anthropometry that includes triceps and biceps skinfolds¹⁰⁶ and mid-arm circumference,¹⁰⁷ (4) Body fat estimation using either bioimpedance analyses or near-infra red interactance,¹⁰⁸⁻¹¹⁰ (5) The Malnutrition-Inflammation Score (MIS)¹¹¹⁻¹¹⁴ including Subjective Global Assessment,¹¹⁵ and (6) Handgrip strength test.¹¹⁶ The dietary education along with the above evaluations usually take 30 minutes to one hour of the dietitian's time during each visit according to our previous and ongoing nutritional clinic operations.

Concurrent Pharmacotherapy and Other Interventions

Regardless of the type of the dietary regimen, participation in the PLADO plan does not interfere with any other aspects of the CKD patient care including prescribed medications such as angiotensin pathway modulators, other anti-hypertensive medications, anti-diabetic medications such as SGLT2 inhibitors, phosphorus binders, potassium binders, sodium bicarbonate, etc. Indeed, it is expected that dietary protein restriction will have a synergistic effect on these pharmacotherapies.⁴⁸ The inclusion of plant-based foods should not necessitate a reduction in any of these medications over time.

Laboratory Tests for Nutritional Management of CKD

Consistent with the pragmatic and cost-efficient nature of the PLADO regimen, all relevant laboratory tests are performed in the clinical laboratories of the respective medical centers typically as part of routine CKD care. With the exception of a semi-

annual serum vitamin B12 level, quarterly to semi-annual laboratory tests include routine chemistry panels (including serum Na, K, CO₂, Cl, urea, creatinine, glucose), liver function tests, hemoglobin A1c, anemia and mineral and bone disorders (MBD) parameters including calcium, phosphorus, and parathyroid hormone. Urinalysis and spot urine for urinary protein/albumin and creatinine should be tested, and eGFR is calculated.¹¹⁷ Participating patients are instructed to collect 24-hour urine samples according to the directions that should be repeated during each ambulatory visit and/or each phone call, i.e., not collecting the first AM urine of Day 1, collecting the first AM urine of Day 2 as the last collection component, and the entire micturition in-between. The 24-hr urine should include measurements of urine urea nitrogen (UUN), sodium (UNa), potassium UK, creatinine (UCr), albumin and protein, as well as urine volume (UV). The following measures should be calculated and reviewed by both the nephrologist and dietitian during each visit:²²

(1) Creatinine clearance: $UCr * UV / SCr$ in ml/min, and to compare to eGFR;

(2) Creatinine index: $UCr / Weight$ (mg/kg), to identify 24-hour urine collection inaccuracies including under- and over-collections by comparing it to the expected value of 1-2 mg/kg/d for women and 1.5-2.5 mg/kg/day for men.

(3) Estimated DPI (eDPI): $UUN * 6.25 + 0.03 * weight$ (in g/kg/day); for patients with substantial proteinuria >3 g/day, the daily proteinuria amount is added to the above eDPI,^{5, 22}

(4) Estimated dietary Na intake: UNa in mmol/44 (g/day);

(5) Estimated dietary K intake: UK in mmol/25 (g/day);

(6) 24-hour urinary protein and albumin excretion (mg/day).

See [Table 5](#) for the overview of the laboratory tests.

Suggested Self-Administered Questionnaires

Based on the goals and the extent of the operation and resources of the CKD clinic, some to all of the following self-administered questionnaires can be used during each or alternating ambulatory visit: (1) Diet, Palatability and Appetite Questionnaire: The appetite component allows grading appetite and recent changes.¹¹⁸ The palatability component includes 12 items and grades palatability and feasibility of dietary intervention.¹¹⁸ These items are combined with diet assessment of the HEMO Study.¹¹⁹ (2) Quality of life KDQOL™ including SF36: This has been used and validated extensively.¹¹³ (3) Uremic symptoms questionnaire: This questionnaire is derived from the “Symptom Assessment Instrument” by Weisbord *et al.*,¹²⁰ which was created and validated in US veterans with stage 5 CKD. (4) Self-Perception and Relationship Questionnaire: This item will assess the psychosocial-spiritual well-being using the 28-item scale.¹²¹ (5) Food Frequency Questionnaire (FFQ):¹²² This questionnaire has been developed by Kalantar-Zadeh *et al.* using the Block FFQ from UC Berkeley, and can be used semi-annually to annually (see [Table 5](#)).

Diet Safety and Transient Dietary Regimen Suspension

Once a patient has completed the 3-month run-in period including dietary education and food preparation training and adjustments, there should be periodic (every 3-6 months) ambulatory visits with continued data collection and review. If PEW signs are observed, or in case of an event that requires suspension of the LPD such as hospitalization with AKI, regardless of dialysis need, or major adverse cardiovascular

events (MACE), the LPD can be transiently suspended, and the patient can resume the LPD and the study protocol at a later time, usually within 90 days of the suspension of the dietary regimen participation if deemed safe. Serum potassium levels >5.5 mEq/L will preferentially be managed by potassium-binders (first line) and/or reducing the potassium-rich components of the diet (second line), as opposed to the current standard of care in that traditional low-potassium dietary adjustments are pursued as the main approach, followed as needed by the administration of potassium-binders.

Challenges and Pitfalls of the Dietary Management of CKD

As stated above, the proposed plant-dominant diet may cause hyperkalemia and could thus be hazardous to patients with advanced CKD. Nephrologists and dietitians should closely monitor patients during the 3-month run-in period and thereafter for adverse events. Dietitian support is necessary for appropriate education on culinary strategies to reduce excessive potassium content while preserving flavor and nutrition. Physicians should take appropriate actions including the use of potassium-binders or suspension of the patient's participation if this should be the safest approach. We do not expect that most patients on plant-based diets will develop hyperkalemia, as these diets are alkalinizing and alter intestinal transit time (see above), especially if dried fruit, juices, smoothies, and sauces can be minimized or avoided along with judicious avoidance of processed food with added potassium-based additives and preservatives.⁷³ Those who are extremely prone to develop hyperkalemia would display this early in the course of the intervention and the PLADO would be discontinued if hyperkalemia cannot

be controlled. Less constipation as a result of PLADO is associated with favorable cardiovascular and renal outcomes.^{123, 124}

It is important to note that the emerging standard of care in CKD is a restricted protein diet of 0.55-0.6 g/kg/day for non-diabetic CD and 0.6-0.8 g/kg/day for diabetic CKD according to the updated KDOQI nutrition guidelines as of September 2020,¹²⁵ and if this is implemented, this is in support of our PLADO regimen. Whereas it is true that a LPD should be the stated goal according to the 2020 KDOQI guidelines, this is typically not followed in everyday clinical practice, where dietary interventions are driven by biochemical abnormalities such as hyperkalemia or hyperphosphatemia. Indeed, prior KDOQI guidelines had recommended DPI of 0.8 g/kg/day without any clear range, which is rarely pursued in a real-world scenario.

It could be argued that under the PLADO regimen there is no clear meal plan. However, this indeed ensures the intended flexibility and pragmatism of the PLADO regimen. The patient and the dietitian should work together in establishing a patient specific “Healthy Kitchen for CKD” and patients and their care-partner should gain experience in implementing patient-centered dietary interventions for CKD management. Careful and balanced industry partnership can be sought to develop innovative “Healthy Kidney Diet Plans” to help people with CKD change their diet to delay the progression of the disease and to defer and prevent kidney failure.

It has been argued that many people with CKD enjoy eating high amounts of meat, and it is highly unlikely that they will adopt a LPD with >50% plant-sources, especially since many dietitians recommend a high protein diet as an approach against obesity and diabetes. Several authors of this review paper, including both nephrologists

and dietitians, have successfully implemented a LPD and plant-dominant diet education in CKD in their respective medical centers. They are aware of the cultural and dietary challenges including in Americans and other Westerners as described in their published reports,⁵ and have been able to introduce and implement the PLADO regimens as described here.

Another potential challenge is the misconception related to the definition of the conservative management of advanced CKD, which is often confused with palliative and supportive care towards the end of life and without requiring special diets. This incorrect assumption is the result of confusing different types of conservative management of CKD, and their similarities and distinctions that have recently been better clarified,⁶ in that a dietary approach including PLADO is a “preservative” management of CKD and a life-sustaining and kidney rejuvenating alternative.

Anticipated Impact and Future Steps

Our proposed PLADO regimen, that has been successfully implemented in several centers in the USA, reinvigorates the role of diet and nutrition in CKD management and may have major clinical and public health implications among numerous populations who are at risk for or have underlying CKD, as well as millions of Americans and people around the world with these conditions. The discussions about plant-dominant diets such as PLADO will also lead to generation of critical data about the efficacy and safety of plant-dominant regimens and will challenge the prevailing dialysis-centered paradigm. It is also aligned with recent US national directives such as the 2020 VA CKD Directive promoting medical nutrition therapy and the July 2019

Executive Order's restructuring of the ESKD program by preemptively involving patients and dietitians in earlier phases of CKD care rather than dialysis preparation. This model stands in sharp contrast to the current payment system whereby the renal dietitians' focus of work is in the dialysis units, while patients at risk of kidney failure have little or no access to nutritional support. The PLADO regimen also innovatively emphasizes the important skillset provided by trained dietitians and other healthcare providers in CKD patient care outside the dialysis arena. Averting and delaying dialysis will also result in major cost benefits to health care systems and likely patient longevity and improved health-related quality of life.

Whereas well-designed, pragmatic randomized controlled trials are warranted to verify the efficacy of PLADO in achieving improvement in clinical end points, this dietary regimen can be used safely for the management of CKD. PLADO has the advantage of consideration of both dietary protein quantity (LPD) and quality (>50% plant-based), instead of quantity alone or being solely plant-based. Its unique pragmatic design efficiently leverages CKD clinic visits and hands-on involvement of nephrologists and dietitians during routine ambulatory nephrology assessments, providing unique feasibility to conduct CKD management successfully. Finally, examining mastery of self-management skills through "Teach-to-Goal" under the "Healthy Kidney through your Kitchen" program by dietitians enable patients with CKD to more effectively self-manage their diet and kidney disease. █

References:

1. Li PK, Garcia-Garcia G, Lui SF, Andreoli S, Fung WW, Hradsky A, Kumaraswami L, Liakopoulos V, Rakhimova Z, Saadi G, Strani L, Ulasi I, Kalantar-Zadeh K and World Kidney Day Steering C. Kidney health for everyone everywhere—from prevention to detection and equitable access to care. *Kidney Int.* 2020;97(2):226-232. doi: 10.1016/j.kint.2019.12.002. PubMed PMID: 31980067. URL: <https://www.ncbi.nlm.nih.gov/pubmed/31980067>.
2. Kalantar-Zadeh K, Crowley ST, Beddhu S, Chen JLT, Daugirdas JT, Goldfarb DS, Jin A, Kovesdy CP, Leehey DJ, Moradi H, Navaneethan SD, Norris KC, Obi Y, O'Hare A, Shafi T, Streja E, Unruh ML, Vachharajani TJ, Weisbord S and Rhee CM. Renal Replacement Therapy and Incremental Hemodialysis for Veterans with Advanced Chronic Kidney Disease. *Semin Dial.* 2017;30(3):251-261. doi: 10.1111/sdi.12601. PubMed PMID: 28421638; PMCID: PMC5418081. URL: <https://www.ncbi.nlm.nih.gov/pubmed/28421638>.
3. Kalantar-Zadeh K, Moore LW, Tortorici AR, Chou JA, St-Jules DE, Aoun A, Rojas-Bautista V, Tschida AK, Rhee CM, Shah AA, Crowley S, Vassalotti JA and Kovesdy CP. North American experience with Low protein diet for Non-dialysis-dependent chronic kidney disease. *BMC Nephrol.* 2016;17(1):90. doi: 10.1186/s12882-016-0304-9. PubMed PMID: 27435088; PMCID: PMC4952055. URL: <http://www.ncbi.nlm.nih.gov/pubmed/27435088>.
4. Saran R, Shahinian V, Pearson A, Tilea A, Steffick D, Wyncott A, Bragg-Gresham J, Heung M, Morgenstern M, Hutton D, Gillespie B, Leichtman A, Zheng K, Young E, O'Hare A, Fischer M, Hotchkiss J, Hynes D, Fried L, Siew E, Balkovetz D, Sovern K, Liu C and Crowley S. Establishing a National Population Health Management System for Kidney Disease: The Veterans Health Administration Renal Information System (VA-REINS). *Am J Kidney Dis.* 2017 5(69):A3. doi: PubMed PMID. URL: [https://www.ajkd.org/article/S0272-6386\(17\)30576-0/pdf](https://www.ajkd.org/article/S0272-6386(17)30576-0/pdf).
5. Saran R, Li Y, Robinson B, Abbott KC, Agodoa LY, Ayanian J, Bragg-Gresham J, Balkrishnan R, Chen JL, Cope E, Eggers PW, Gillen D, Gipson D, Hailpern SM, Hall YN, He K, Herman W, Heung M, Hirth RA, Hutton D, Jacobsen SJ, Kalantar-Zadeh K, Kovesdy CP, Lu Y, Molnar MZ, Morgenstern H, Nallamothu B, Nguyen DV, O'Hare AM, Plattner B, Pisoni R, Port FK, Rao P, Rhee CM, Sakhuja A, Schaubel DE, Selewski DT, Shahinian V, Sim JJ, Song P, Streja E, Kurella Tamura M, Tentori F, White S, Woodside K and Hirth RA. US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. *Am J Kidney Dis.* 2016;67(3 Suppl 1):Svii, S1-305. doi: 10.1053/j.ajkd.2015.12.014. PubMed PMID: 26925525. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26925525>.
6. Saran R, Li Y, Robinson B, Ayanian J, Balkrishnan R, Bragg-Gresham J, Chen JT, Cope E, Gipson D, He K, Herman W, Heung M, Hirth RA, Jacobsen SS, Kalantar-Zadeh K, Kovesdy CP, Leichtman AB, Lu Y, Molnar MZ, Morgenstern H, Nallamothu B, O'Hare AM, Pisoni R, Plattner B, Port FK, Rao P, Rhee CM, Schaubel DE, Selewski DT, Shahinian V, Sim JJ, Song P, Streja E, Kurella Tamura M, Tentori F, Eggers PW, Agodoa LY and Abbott KC. US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. *Am J Kidney Dis.* 2015;66(1 Suppl 1):Svii, S1-305. doi: 10.1053/j.ajkd.2015.05.001. PubMed PMID: 26111994. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26111994>.
7. Wang V, Maciejewski ML, Patel UD, Stechuchak KM, Hynes DM and Weinberger M. Comparison of outcomes for veterans receiving dialysis care from VA and non-VA providers. *BMC health services research.* 2013;13:26. doi: 10.1186/1472-6963-13-26. PubMed PMID: 23327632; PMCID: PMC3559268. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23327632>.
8. Streja E, Kovesdy CP, Soohoo M, Obi Y, Rhee CM, Park C, Chen JLT, Nakata T, Nguyen DV, Amin AN, Jacobsen SJ, Sim JJ and Kalantar-Zadeh K. Dialysis Provider and Outcomes among United States Veterans Who Transition to Dialysis. *Clin J Am Soc Nephrol.* 2018;13(7):1055-

1062. doi: 10.2215/CJN.12951117. PubMed PMID: 29903898; PMCID: PMC6032569. URL: <https://www.ncbi.nlm.nih.gov/pubmed/29903898>.
9. Kalantar-Zadeh K, Wightman A and Liao S. Ensuring Choice for People with Kidney Failure — Dialysis, Supportive Care, and Hope. *N Engl J Med*. 2020 [in press]. doi. PubMed PMID.
10. Kurella Tamura M, Covinsky KE, Chertow GM, Yaffe K, Landefeld CS and McCulloch CE. Functional status of elderly adults before and after initiation of dialysis. *N Engl J Med*. 2009;361(16):1539-47. Epub 2009/10/16. doi: 10.1056/NEJMoa0904655. PubMed PMID: 19828531; PMCID: 2789552. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19828531>.
11. Kalantar-Zadeh K and Li PK. Strategies to prevent kidney disease and its progression. *Nat Rev Nephrol*. 2020;16(3):129-130. doi: 10.1038/s41581-020-0253-1. PubMed PMID: 32005966. URL: <https://www.ncbi.nlm.nih.gov/pubmed/32005966>.
12. Moore LW and Kalantar-Zadeh K. Implementing the "Advancing American Kidney Health Initiative" by Leveraging Nutritional and Dietary Management of Kidney Patients. *J Ren Nutr*. 2019;29(5):357-360. doi: 10.1053/j.jrn.2019.07.004. PubMed PMID: 31472903. URL: <https://www.ncbi.nlm.nih.gov/pubmed/31472903>.
13. Ko GJ, Kalantar-Zadeh K, Goldstein-Fuchs J and Rhee CM. Dietary Approaches in the Management of Diabetic Patients with Kidney Disease. *Nutrients*. 2017;9(8). doi: 10.3390/nu9080824. PubMed PMID: 28758978; PMCID: PMC5579617. URL: <https://www.ncbi.nlm.nih.gov/pubmed/28758978>.
14. Moore LW, Byham-Gray LD, Scott Parrott J, Rigassio-Radler D, Mandayam S, Jones SL, Mitch WE and Osama Gaber A. The mean dietary protein intake at different stages of chronic kidney disease is higher than current guidelines. *Kidney Int*. 2013;83(4):724-32. doi: 10.1038/ki.2012.420. PubMed PMID: 23302719. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23302719>.
15. Pasiakos SM, Lieberman HR and Fulgoni VL, 3rd. Higher-protein diets are associated with higher HDL cholesterol and lower BMI and waist circumference in US adults. *J Nutr*. 2015;145(3):605-14. doi: 10.3945/jn.114.205203. PubMed PMID: 25733478. URL: <https://www.ncbi.nlm.nih.gov/pubmed/25733478>.
16. Athinarayanan SJ, Adams RN, Hallberg SJ, McKenzie AL, Bhanpuri NH, Campbell WW, Volek JS, Phinney SD and McCarter JP. Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial. *Front Endocrinol (Lausanne)*. 2019;10:348. doi: 10.3389/fendo.2019.00348. PubMed PMID: 31231311; PMCID: PMC6561315. URL: <https://www.ncbi.nlm.nih.gov/pubmed/31231311>.
17. Ko G-J, Rhee CM, Kalantar-Zadeh K and Joshi S. The Impact of High Protein Diets on Kidney Health and Longevity. *J Am Soc Nephrol*. 2020 [in press]. doi. PubMed PMID.
18. Kamper AL and Strandgaard S. Long-Term Effects of High-Protein Diets on Renal Function. *Annu Rev Nutr*. 2017;37:347-369. doi: 10.1146/annurev-nutr-071714-034426. PubMed PMID: 28637384. URL: <https://www.ncbi.nlm.nih.gov/pubmed/28637384>.
19. Kalantar-Zadeh K, Kramer HM and Fouque D. High-protein diet is bad for kidney health: unleashing the taboo. *Nephrol Dial Transplant*. 2020;35(1):1-4. doi: 10.1093/ndt/gfz216. PubMed PMID: 31697325. URL: <https://www.ncbi.nlm.nih.gov/pubmed/31697325>.
20. Kime P. VA Eyes Keto Diet-Based Diabetes Treatment, But Questions Remain. *Military-dot-com*. 2019, July 9,;on-line. doi. PubMed PMID. URL: <https://www.military.com/daily-news/2019/07/09/va-eyes-keto-diet-based-diabetes-treatment-questions-remain.html>.
21. Joshi S, Ostfeld RJ and McMacken M. The Ketogenic Diet for Obesity and Diabetes-Enthusiasm Outpaces Evidence. *JAMA internal medicine*. 2019;179(9):1163-1164. doi:

- 10.1001/jamainternmed.2019.2633. PubMed PMID: 31305866. URL: <https://www.ncbi.nlm.nih.gov/pubmed/31305866>.
22. Kalantar-Zadeh K and Fouque D. Nutritional Management of Chronic Kidney Disease. *N Engl J Med*. 2017;377(18):1765-1776. doi: 10.1056/NEJMra1700312. PubMed PMID: 29091561. URL: <https://www.ncbi.nlm.nih.gov/pubmed/29091561>.
23. Malhotra R, Lipworth L, Cavanaugh KL, Young BA, Tucker KL, Carithers TC, Taylor HA, Correa A, Kabagambe EK and Ikizler TA. Protein Intake and Long-term Change in Glomerular Filtration Rate in the Jackson Heart Study. *J Ren Nutr*. 2018;28(4):245-250. doi: 10.1053/j.jrn.2017.11.008. PubMed PMID: 29452887. URL: <https://www.ncbi.nlm.nih.gov/pubmed/29452887>.
24. Fouque D, Laville M, Boissel JP, Chifflet R, Labeuw M and Zech PY. Controlled low protein diets in chronic renal insufficiency: meta-analysis. *BMJ*. 1992;304(6821):216-20. doi. PubMed PMID: 1531426; PMCID: PMC1881445. URL: <http://www.ncbi.nlm.nih.gov/pubmed/1531426>.
25. Chewcharat A, Takkavatakarn K, Wongrattanagorn S, Panrong K, Kittiskulnam P, Eiam-Ong S and Susantitaphong P. The Effects of Restricted Protein Diet Supplemented With Ketoanalogue on Renal Function, Blood Pressure, Nutritional Status, and Chronic Kidney Disease-Mineral and Bone Disorder in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. *J Ren Nutr*. 2019. doi: 10.1053/j.jrn.2019.07.005. PubMed PMID: 31607548. URL: <https://www.ncbi.nlm.nih.gov/pubmed/31607548>.
26. Rhee CM, Ahmadi SF, Kovesdy CP and Kalantar-Zadeh K. Low-protein diet for conservative management of chronic kidney disease: a systematic review and meta-analysis of controlled trials. *J Cachexia Sarcopenia Muscle*. 2018;9(2):235-245. doi: 10.1002/jcsm.12264. PubMed PMID: 29094800; PMCID: PMC5879959. URL: <https://www.ncbi.nlm.nih.gov/pubmed/29094800>.
27. Jiang Z, Zhang X, Yang L, Li Z and Qin W. Effect of restricted protein diet supplemented with keto analogues in chronic kidney disease: a systematic review and meta-analysis. *Int Urol Nephrol*. 2016;48(3):409-18. doi: 10.1007/s11255-015-1170-2. PubMed PMID: 26620578. URL: <https://www.ncbi.nlm.nih.gov/pubmed/26620578>.
28. Metzger M, Yuan WL, Haymann JP, Flamant M, Houillier P, Thervet E, Boffa JJ, Vrtovnik F, Froissart M, Bankir L, Fouque D and Stengel B. Association of a Low-Protein Diet With Slower Progression of CKD. *Kidney Int Rep*. 2018;3(1):105-114. doi: 10.1016/j.ekir.2017.08.010. PubMed PMID: 29340320; PMCID: PMC5762958. URL: <https://www.ncbi.nlm.nih.gov/pubmed/29340320>.
29. Tantisattamo E, Dafoe DC, Reddy UG, Ichii H, Rhee CM, Streja E, Landman J and Kalantar-Zadeh K. Current Management of Patients With Acquired Solitary Kidney. *Kidney Int Rep*. 2019;4(9):1205-1218. doi: 10.1016/j.ekir.2019.07.001. PubMed PMID: 31517140; PMCID: PMC6732776. URL: <https://www.ncbi.nlm.nih.gov/pubmed/31517140>.
30. Tuttle KR, Bruton JL, Perusek MC, Lancaster JL, Kopp DT and DeFronzo RA. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. *N Engl J Med*. 1991;324(23):1626-32. doi: 10.1056/NEJM199106063242304. PubMed PMID: 2030719. URL: <https://www.ncbi.nlm.nih.gov/pubmed/2030719>.
31. Kalantar-Zadeh K and Moore LW. Does Kidney Longevity Mean Healthy Vegan Food and Less Meat or Is Any Low-Protein Diet Good Enough? *J Ren Nutr*. 2019;29(2):79-81. doi: 10.1053/j.jrn.2019.01.008. PubMed PMID: 30782404. URL: <https://www.ncbi.nlm.nih.gov/pubmed/30782404>.

32. Joshi S, Shah S and Kalantar-Zadeh K. Adequacy of Plant-Based Proteins in Chronic Kidney Disease. *J Ren Nutr*. 2019;29(2):112-117. doi: 10.1053/j.jrn.2018.06.006. PubMed PMID: 30122652. URL: <https://www.ncbi.nlm.nih.gov/pubmed/30122652>.
33. Pasiakos SM, Agarwal S, Lieberman HR and Fulgoni VL, 3rd. Sources and Amounts of Animal, Dairy, and Plant Protein Intake of US Adults in 2007-2010. *Nutrients*. 2015;7(8):7058-69. doi: 10.3390/nu7085322. PubMed PMID: 26308049; PMCID: PMC4555161. URL: <https://www.ncbi.nlm.nih.gov/pubmed/26308049>.
34. Jia Y, Hwang SY, House JD, Ogborn MR, Weiler HA, O K and Aukema HM. Long-term high intake of whole proteins results in renal damage in pigs. *J Nutr*. 2010;140(9):1646-52. doi: 10.3945/jn.110.123034. PubMed PMID: 20668252. URL: <https://www.ncbi.nlm.nih.gov/pubmed/20668252>.
35. Joshi S, Hashmi S, Shah S and Kalantar-Zadeh K. Plant-based diets for prevention and management of chronic kidney disease. *Curr Opin Nephrol Hypertens*. 2020;29(1):16-21. doi: 10.1097/MNH.0000000000000574. PubMed PMID: 31725014. URL: <https://www.ncbi.nlm.nih.gov/pubmed/31725014>.
36. Tantisattamo E, Hanna RM, Reddy UG, Ichii H, Dafoe DC, Danovitch GM and Kalantar-Zadeh K. Novel options for failing allograft in kidney transplanted patients to avoid or defer dialysis therapy. *Curr Opin Nephrol Hypertens*. 2020;29(1):80-91. doi: 10.1097/MNH.0000000000000572. PubMed PMID: 31743241. URL: <https://www.ncbi.nlm.nih.gov/pubmed/31743241>.
37. Joshi S, McMacken M and Kalantar-Zadeh K. Plant-Based Diets for Kidney Disease: A Guide for Clinicians. *Am J Kidney Dis*. 2020 [in press]. doi. PubMed PMID.
38. Chauveau P and Lasseur C. Plant-based Protein Intake and Kidney Function in Diabetic Patients. *Kidney Int Rep*. 2019;4(5):638-639. doi: 10.1016/j.ekir.2019.03.013. PubMed PMID: 31080916; PMCID: PMC6506755. URL: <https://www.ncbi.nlm.nih.gov/pubmed/31080916>.
39. Campbell TM and Liebman SE. Plant-based dietary approach to stage 3 chronic kidney disease with hyperphosphataemia. *BMJ case reports*. 2019;12(12). doi: 10.1136/bcr-2019-232080. PubMed PMID: 31874846; PMCID: PMC6936381. URL: <https://www.ncbi.nlm.nih.gov/pubmed/31874846>.
40. Moorthi RN, Vorland CJ and Hill Gallant KM. Diet and Diabetic Kidney Disease: Plant Versus Animal Protein. *Curr Diab Rep*. 2017;17(3):15. doi: 10.1007/s11892-017-0843-x. PubMed PMID: 28271467; PMCID: PMC5503680. URL: <https://www.ncbi.nlm.nih.gov/pubmed/28271467>.
41. Clegg DJ and Hill Gallant KM. Plant-Based Diets in CKD. *Clin J Am Soc Nephrol*. 2019;14(1):141-143. doi: 10.2215/CJN.08960718. PubMed PMID: 30587492; PMCID: PMC6364543. URL: <https://www.ncbi.nlm.nih.gov/pubmed/30587492>.
42. Kontessis P, Jones S, Dodds R, Trevisan R, Nosadini R, Fioretto P, Borsato M, Sacerdoti D and Viberti G. Renal, metabolic and hormonal responses to ingestion of animal and vegetable proteins. *Kidney Int*. 1990;38(1):136-44. doi. PubMed PMID: 2166857. URL: <https://www.ncbi.nlm.nih.gov/pubmed/2166857>.
43. Lin J, Hu FB and Curhan GC. Associations of diet with albuminuria and kidney function decline. *Clin J Am Soc Nephrol*. 2010;5(5):836-43. doi: 10.2215/CJN.08001109. PubMed PMID: 20299364; PMCID: PMC2863979. URL: <https://www.ncbi.nlm.nih.gov/pubmed/20299364>.
44. Kim H, Caulfield LE, Garcia-Larsen V, Steffen LM, Grams ME, Coresh J and Rebholz CM. Plant-Based Diets and Incident CKD and Kidney Function. *Clin J Am Soc Nephrol*. 2019;14(5):682-691. doi: 10.2215/CJN.12391018. PubMed PMID: 31023928; PMCID: PMC6500948. URL: <https://www.ncbi.nlm.nih.gov/pubmed/31023928>.

45. Haring B, Selvin E, Liang M, Coresh J, Grams ME, Petruski-Ivleva N, Steffen LM and Rebholz CM. Dietary Protein Sources and Risk for Incident Chronic Kidney Disease: Results From the Atherosclerosis Risk in Communities (ARIC) Study. *J Ren Nutr*. 2017;27(4):233-242. doi: 10.1053/j.jrn.2016.11.004. PubMed PMID: 28065493; PMCID: PMC5476496. URL: <https://www.ncbi.nlm.nih.gov/pubmed/28065493>.
46. Chen X, Wei G, Jalili T, Metos J, Giri A, Cho ME, Boucher R, Greene T and Beddhu S. The Associations of Plant Protein Intake With All-Cause Mortality in CKD. *Am J Kidney Dis*. 2016;67(3):423-30. doi: 10.1053/j.ajkd.2015.10.018. PubMed PMID: 26687923; PMCID: PMC4769135. URL: <https://www.ncbi.nlm.nih.gov/pubmed/26687923>.
47. Joshi S, Shah S and Kalantar-Zadeh K. Adequacy of Plant-Based Proteins in Chronic Kidney Disease. *J Ren Nutr*. 2018 [epub] / 2019. doi: 10.1053/j.jrn.2018.06.006. PubMed PMID: 30122652. URL: <https://www.ncbi.nlm.nih.gov/pubmed/30122652>.
48. Koppe L and Fouque D. The Role for Protein Restriction in Addition to Renin-Angiotensin-Aldosterone System Inhibitors in the Management of CKD. *Am J Kidney Dis*. 2019;73(2):248-257. doi: 10.1053/j.ajkd.2018.06.016. PubMed PMID: 30149957. URL: <https://www.ncbi.nlm.nih.gov/pubmed/30149957>.
49. Pignanelli M, Bogiatzi C, Gloor G, Allen-Vercoe E, Reid G, Urquhart BL, Ruetz KN, Velenosi TJ and Spence JD. Moderate Renal Impairment and Toxic Metabolites Produced by the Intestinal Microbiome: Dietary Implications. *J Ren Nutr*. 2018. doi: 10.1053/j.jrn.2018.05.007. PubMed PMID: 30100156. URL: <https://www.ncbi.nlm.nih.gov/pubmed/30100156>.
50. Fogelman AM. TMAO is both a biomarker and a renal toxin. *Circ Res*. 2015;116(3):396-7. doi: 10.1161/CIRCRESAHA.114.305680. PubMed PMID: 25634968; PMCID: PMC4366001. URL: <https://www.ncbi.nlm.nih.gov/pubmed/25634968>.
51. McFarlane C, Ramos CI, Johnson DW and Campbell KL. Prebiotic, Probiotic, and Synbiotic Supplementation in Chronic Kidney Disease: A Systematic Review and Meta-analysis. *J Ren Nutr*. 2018. doi: 10.1053/j.jrn.2018.08.008. PubMed PMID: 30366767. URL: <https://www.ncbi.nlm.nih.gov/pubmed/30366767>.
52. Black AP, Anjos JS, Cardozo L, Carmo FL, Dolenga CJ, Nakao LS, de Carvalho Ferreira D, Rosado A, Carraro Eduardo JC and Mafra D. Does Low-Protein Diet Influence the Uremic Toxin Serum Levels From the Gut Microbiota in Nondialysis Chronic Kidney Disease Patients? *J Ren Nutr*. 2018;28(3):208-214. doi: 10.1053/j.jrn.2017.11.007. PubMed PMID: 29439931. URL: <https://www.ncbi.nlm.nih.gov/pubmed/29439931>.
53. Rodrigues Neto Angeloco L, Arces de Souza GC, Almeida Romao E and Garcia Chiarello P. Alkaline Diet and Metabolic Acidosis: Practical Approaches to the Nutritional Management of Chronic Kidney Disease. *J Ren Nutr*. 2018;28(3):215-220. doi: 10.1053/j.jrn.2017.10.006. PubMed PMID: 29221627. URL: <https://www.ncbi.nlm.nih.gov/pubmed/29221627>.
54. Moorthi RN, Armstrong CL, Janda K, Ponsler-Sipes K, Asplin JR and Moe SM. The effect of a diet containing 70% protein from plants on mineral metabolism and musculoskeletal health in chronic kidney disease. *Am J Nephrol*. 2014;40(6):582-91. doi: 10.1159/000371498. PubMed PMID: 25613675; PMCID: PMC4374343. URL: <https://www.ncbi.nlm.nih.gov/pubmed/25613675>.
55. Watanabe MT, Barretti P and Caramori JCT. Dietary Intervention in Phosphatemia Control-Nutritional Traffic Light Labeling. *J Ren Nutr*. 2018;28(6):e45-e47. doi: 10.1053/j.jrn.2018.04.005. PubMed PMID: 29751995. URL: <https://www.ncbi.nlm.nih.gov/pubmed/29751995>.
56. Watanabe MT, Barretti P and Caramori JCT. Attention to Food Phosphate and Nutrition Labeling. *J Ren Nutr*. 2018;28(4):e29-e31. doi: 10.1053/j.jrn.2017.12.013. PubMed PMID: 29731236. URL: <https://www.ncbi.nlm.nih.gov/pubmed/29731236>.

57. Demirci BG, Tural E, Eminsoy IO, Kulah E and Sezer S. Dietary Fiber Intake: Its Relation With Glycation End Products and Arterial Stiffness in End-Stage Renal Disease Patients. *J Ren Nutr*. 2018. doi: 10.1053/j.jrn.2018.08.007. PubMed PMID: 30314838. URL: <https://www.ncbi.nlm.nih.gov/pubmed/30314838>.
58. Chiavaroli L, Mirrahimi A, Sievenpiper JL, Jenkins DJ and Darling PB. Dietary fiber effects in chronic kidney disease: a systematic review and meta-analysis of controlled feeding trials. *Eur J Clin Nutr*. 2015;69(7):761-8. doi: 10.1038/ejcn.2014.237. PubMed PMID: 25387901. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25387901>.
59. Parpia AS, L'Abbe M, Goldstein M, Arcand J, Magnuson B and Darling PB. The Impact of Additives on the Phosphorus, Potassium, and Sodium Content of Commonly Consumed Meat, Poultry, and Fish Products Among Patients With Chronic Kidney Disease. *J Ren Nutr*. 2018;28(2):83-90. doi: 10.1053/j.jrn.2017.08.013. PubMed PMID: 29146137. URL: <https://www.ncbi.nlm.nih.gov/pubmed/29146137>.
60. Picard K. Potassium Additives and Bioavailability: Are We Missing Something in Hyperkalemia Management? *J Ren Nutr*. 2018. doi: 10.1053/j.jrn.2018.10.003. PubMed PMID: 30579674. URL: <https://www.ncbi.nlm.nih.gov/pubmed/30579674>.
61. Hirahatake KM, Jacobs DR, Gross MD, Bibbins-Domingo KB, Shlipak MG, Mattix-Kramer H and Odegaard AO. The Association of Serum Carotenoids, Tocopherols, and Ascorbic Acid With Rapid Kidney Function Decline: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. *J Ren Nutr*. 2018. doi: 10.1053/j.jrn.2018.05.008. PubMed PMID: 30098859. URL: <https://www.ncbi.nlm.nih.gov/pubmed/30098859>.
62. Rapa SF, Di Iorio BR, Campiglia P, Heidland A and Marzocco S. Inflammation and Oxidative Stress in Chronic Kidney Disease-Potential Therapeutic Role of Minerals, Vitamins and Plant-Derived Metabolites. *Int J Mol Sci*. 2019;21(1). doi: 10.3390/ijms21010263. PubMed PMID: 31906008; PMCID: PMC6981831. URL: <https://www.ncbi.nlm.nih.gov/pubmed/31906008>.
63. Mills KT, Chen J, Yang W, Appel LJ, Kusek JW, Alper A, Delafontaine P, Keane MG, Mohler E, Ojo A, Rahman M, Ricardo AC, Soliman EZ, Steigerwalt S, Townsend R, He J and Chronic Renal Insufficiency Cohort Study I. Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease. *JAMA*. 2016;315(20):2200-10. doi: 10.1001/jama.2016.4447. PubMed PMID: 27218629; PMCID: PMC5087595. URL: <https://www.ncbi.nlm.nih.gov/pubmed/27218629>.
64. Lee SW, Kim YS, Kim YH, Chung W, Park SK, Choi KH, Ahn C and Oh KH. Dietary Protein Intake, Protein Energy Wasting, and the Progression of Chronic Kidney Disease: Analysis from the KNOW-CKD Study. *Nutrients*. 2019;11(1). doi: 10.3390/nu11010121. PubMed PMID: 30626166; PMCID: PMC6356719. URL: <https://www.ncbi.nlm.nih.gov/pubmed/30626166>.
65. Morris A, Krishnan N, Kimani PK and Lycett D. Effect of Dietary Potassium Restriction on Serum Potassium, Disease Progression, and Mortality in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. *J Ren Nutr*. 2019. doi: 10.1053/j.jrn.2019.09.009. PubMed PMID: 31734057. URL: <https://www.ncbi.nlm.nih.gov/pubmed/31734057>.
66. Noori N, Kalantar-Zadeh K, Kovesdy CP, Bross R, Benner D and Kopple JD. Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients. *Clin J Am Soc Nephrol*. 2010;5(4):683-92. doi: 10.2215/CJN.08601209. PubMed PMID: 20185606; PMCID: 2849686. URL: <http://www.ncbi.nlm.nih.gov/pubmed/20185606>.
67. St-Jules DE, Goldfarb DS and Sevick MA. Nutrient Non-equivalence: Does Restricting High-Potassium Plant Foods Help to Prevent Hyperkalemia in Hemodialysis Patients? *J Ren Nutr*. 2016;26(5):282-7. doi: 10.1053/j.jrn.2016.02.005. PubMed PMID: 26975777. URL: <https://www.ncbi.nlm.nih.gov/pubmed/26975777>.

68. Cupisti A, D'Alessandro C, Gesualdo L, Cosola C, Gallieni M, Egidi MF and Fusaro M. Non-Traditional Aspects of Renal Diets: Focus on Fiber, Alkali and Vitamin K1 Intake. *Nutrients*. 2017;9(5). doi: 10.3390/nu9050444. PubMed PMID: 28468236; PMCID: PMC5452174. URL: <https://www.ncbi.nlm.nih.gov/pubmed/28468236>.
69. Evenepoel P and Meijers BK. Dietary fiber and protein: nutritional therapy in chronic kidney disease and beyond. *Kidney Int*. 2012;81(3):227-9. doi: 10.1038/ki.2011.394. PubMed PMID: 22241557. URL: <https://www.ncbi.nlm.nih.gov/pubmed/22241557>.
70. Xu H, Huang X, Riserus U, Krishnamurthy VM, Cederholm T, Arnlov J, Lindholm B, Sjogren P and Carrero JJ. Dietary fiber, kidney function, inflammation, and mortality risk. *Clin J Am Soc Nephrol*. 2014;9(12):2104-10. doi: 10.2215/CJN.02260314. PubMed PMID: 25280496; PMCID: PMC4255398. URL: <https://www.ncbi.nlm.nih.gov/pubmed/25280496>.
71. Krishnamurthy VM, Wei G, Baird BC, Murtaugh M, Chonchol MB, Raphael KL, Greene T and Beddhu S. High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. *Kidney Int*. 2012;81(3):300-6. doi: 10.1038/ki.2011.355. PubMed PMID: 22012132; PMCID: PMC4704855. URL: <https://www.ncbi.nlm.nih.gov/pubmed/22012132>.
72. Kalantar-Zadeh K and Ikizler TA. Let them eat during dialysis: an overlooked opportunity to improve outcomes in maintenance hemodialysis patients. *J Ren Nutr*. 2013;23(3):157-63. doi: 10.1053/j.jrn.2012.11.001. PubMed PMID: 23313434; PMCID: PMC3632653. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23313434>.
73. Cupisti A, Kovesdy CP, D'Alessandro C and Kalantar-Zadeh K. Dietary Approach to Recurrent or Chronic Hyperkalemia in Patients with Decreased Kidney Function. *Nutrients*. 2018;10(3). doi: 10.3390/nu10030261. PubMed PMID: 29495340; PMCID: PMC5872679. URL: <https://www.ncbi.nlm.nih.gov/pubmed/29495340>.
74. Kalantar-Zadeh K. Patient education for phosphorus management in chronic kidney disease. *Patient preference and adherence*. 2013;7:379-90. doi: 10.2147/PPA.S43486. PubMed PMID: 23667310; PMCID: 3650565. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23667310>.
75. Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH and Kopple JD. Appetite and inflammation, nutrition, anemia and clinical outcome in hemodialysis patients. *Am J Clin Nutr*. 2004;80(2):299-307. doi: PubMed PMID.
76. Guebre-Egziabher F, Debard C, Draï J, Denis L, Pesenti S, Bienvenu J, Vidal H, Laville M and Fouque D. Differential dose effect of fish oil on inflammation and adipose tissue gene expression in chronic kidney disease patients. *Nutrition*. 2013;29(5):730-6. doi: 10.1016/j.nut.2012.10.011. PubMed PMID: 23375525. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23375525>.
77. Kalantar-Zadeh K, Braglia A, Chow J, Kwon O, Kuwae N, Colman S, Cockram DB and Kopple JD. An anti-inflammatory and antioxidant nutritional supplement for hypoalbuminemic hemodialysis patients: a pilot/feasibility study. *J Ren Nutr*. 2005;15(3):318-31. doi: 10.1016/j.jrn.2005.04.004. PubMed PMID: 16007562. URL: <https://www.ncbi.nlm.nih.gov/pubmed/16007562>.
78. Rattanasompattikul M, Molnar MZ, Lee ML, Dukkipati R, Bross R, Jing J, Kim Y, Voss AC, Benner D, Feroze U, Macdougall IC, Tayek JA, Norris KC, Kopple JD, Unruh M, Kovesdy CP and Kalantar-Zadeh K. Anti-Inflammatory and Anti-Oxidative Nutrition in Hypoalbuminemic Dialysis Patients (AIONID) study: results of the pilot-feasibility, double-blind, randomized, placebo-controlled trial. *J Cachexia Sarcopenia Muscle*. 2013;4(4):247-57. doi: 10.1007/s13539-013-0115-9. PubMed PMID: 24052226; PMCID: PMC3830006. URL: <http://www.ncbi.nlm.nih.gov/pubmed/24052226>.

79. Soohoo M, Ahmadi SF, Qader H, Streja E, Obi Y, Moradi H, Rhee CM, Kim TH, Kovesdy CP and Kalantar-Zadeh K. Association of serum vitamin B12 and folate with mortality in incident hemodialysis patients. *Nephrol Dial Transplant*. 2017;32(6):1024-1032. doi: 10.1093/ndt/gfw090. PubMed PMID: 27190367. URL: <https://www.ncbi.nlm.nih.gov/pubmed/27190367>.
80. Li XS, Wang Z, Cajka T, Buffa JA, Nemet I, Hurd AG, Gu X, Skye SM, Roberts AB, Wu Y, Li L, Shahan CJ, Wagner MA, Hartiala JA, Kerby RL, Romano KA, Han Y, Obeid S, Luscher TF, Allayee H, Rey FE, DiDonato JA, Fiehn O, Tang WHW and Hazen SL. Untargeted metabolomics identifies trimethyllysine, a TMAO-producing nutrient precursor, as a predictor of incident cardiovascular disease risk. *JCI Insight*. 2018;3(6). doi: 10.1172/jci.insight.99096. PubMed PMID: 29563342; PMCID: PMC5926943. URL: <https://www.ncbi.nlm.nih.gov/pubmed/29563342>.
81. Koeth RA, Lam-Galvez BR, Kirsop J, Wang Z, Levison BS, Gu X, Copeland MF, Bartlett D, Cody DB, Dai HJ, Culley MK, Li XS, Fu X, Wu Y, Li L, DiDonato JA, Tang WHW, Garcia-Garcia JC and Hazen SL. L-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. *J Clin Invest*. 2019;129(1):373-387. doi: 10.1172/JCI94601. PubMed PMID: 30530985; PMCID: PMC6307959. URL: <https://www.ncbi.nlm.nih.gov/pubmed/30530985>.
82. Smits LP, Kootte RS, Levin E, Prodan A, Fuentes S, Zoetendal EG, Wang Z, Levison BS, Cleophas MCP, Kemper EM, Dallinga-Thie GM, Groen AK, Joosten LAB, Netea MG, Stroes ESG, de Vos WM, Hazen SL and Nieuwdorp M. Effect of Vegan Fecal Microbiota Transplantation on Carnitine- and Choline-Derived Trimethylamine-N-Oxide Production and Vascular Inflammation in Patients With Metabolic Syndrome. *J Am Heart Assoc*. 2018;7(7). doi: 10.1161/JAHA.117.008342. PubMed PMID: 29581220; PMCID: PMC5907601. URL: <https://www.ncbi.nlm.nih.gov/pubmed/29581220>.
83. Vaziri ND, Goshtasbi N, Yuan J, Jellbauer S, Moradi H, Raffatellu M and Kalantar-Zadeh K. Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium. *Am J Nephrol*. 2012;36(5):438-43. doi: 10.1159/000343886. PubMed PMID: 23128155; PMCID: PMC3725306. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23128155>.
84. Lau WL, Kalantar-Zadeh K and Vaziri ND. The Gut as a Source of Inflammation in Chronic Kidney Disease. *Nephron*. 2015;130(2):92-8. doi: 10.1159/000381990. PubMed PMID: 25967288; PMCID: PMC4485546. URL: <https://www.ncbi.nlm.nih.gov/pubmed/25967288>.
85. Vaziri ND, Yuan J, Rahimi A, Ni Z, Said H and Subramanian VS. Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. *Nephrol Dial Transplant*. 2012;27(7):2686-93. doi: 10.1093/ndt/gfr624. PubMed PMID: 22131233. URL: <http://www.ncbi.nlm.nih.gov/pubmed/22131233>.
86. Vaziri ND, Yuan J, Nazertehrani S, Ni Z and Liu S. Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. *Am J Nephrol*. 2013;38(2):99-103. doi: 10.1159/000353764. PubMed PMID: 23887095. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23887095>.
87. Magnusson M, Magnusson KE, Sundqvist T and Denneberg T. Increased intestinal permeability to differently sized polyethylene glycols in uremic rats: effects of low- and high-protein diets. *Nephron*. 1990;56(3):306-11. doi: PubMed PMID: 2077413. URL: <http://www.ncbi.nlm.nih.gov/pubmed/2077413>.
88. Magnusson M, Magnusson KE, Sundqvist T and Denneberg T. Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. *Gut*. 1991;32(7):754-9. doi: PubMed PMID: 1855681; PMCID: PMC1378990. URL: <http://www.ncbi.nlm.nih.gov/pubmed/1855681>.
89. Lau WL, Liu SM, Pahlevan S, Yuan J, Khazaeli M, Ni Z, Chan JY and Vaziri ND. Role of Nrf2 dysfunction in uremia-associated intestinal inflammation and epithelial barrier disruption. *Dig*

- Dis Sci.* 2015;60(5):1215-22. doi: 10.1007/s10620-014-3428-4. PubMed PMID: 25399330. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25399330>.
90. Wang F, Jiang H, Shi K, Ren Y, Zhang P and Cheng S. Gut bacterial translocation is associated with microinflammation in end-stage renal disease patients. *Nephrology (Carlton)*. 2012;17(8):733-8. doi: 10.1111/j.1440-1797.2012.01647.x. PubMed PMID: 22817644. URL: <http://www.ncbi.nlm.nih.gov/pubmed/22817644>.
91. Shi K, Wang F, Jiang H, Liu H, Wei M, Wang Z and Xie L. Gut bacterial translocation may aggravate microinflammation in hemodialysis patients. *Dig Dis Sci.* 2014;59(9):2109-17. doi: 10.1007/s10620-014-3202-7. PubMed PMID: 24828917. URL: <http://www.ncbi.nlm.nih.gov/pubmed/24828917>.
92. Feroze U, Kalantar-Zadeh K, Sterling KA, Molnar MZ, Noori N, Benner D, Shah V, Dwivedi R, Becker K, Kovesdy CP and Raj DS. Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. *J Ren Nutr.* 2012;22(3):317-26. doi: 10.1053/j.jrn.2011.05.004. PubMed PMID: 21880509; PMCID: 3242161. URL: <http://www.ncbi.nlm.nih.gov/pubmed/21880509>.
93. Szeto CC, Kwan BC, Chow KM, Lai KB, Chung KY, Leung CB and Li PK. Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. *Clin J Am Soc Nephrol.* 2008;3(2):431-6. doi: 10.2215/CJN.03600807. PubMed PMID: 18256376; PMCID: PMC2390956. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18256376>.
94. Rossi M, Campbell KL, Johnson DW, Stanton T, Vesey DA, Coombes JS, Weston KS, Hawley CM, McWhinney BC, Ungerer JP and Isbel N. Protein-bound uremic toxins, inflammation and oxidative stress: a cross-sectional study in stage 3-4 chronic kidney disease. *Arch Med Res.* 2014;45(4):309-17. doi: 10.1016/j.arcmed.2014.04.002. PubMed PMID: 24751327. URL: <http://www.ncbi.nlm.nih.gov/pubmed/24751327>.
95. McIntyre CW, Harrison LE, Eldehni MT, Jefferies HJ, Szeto CC, John SG, Sigrist MK, Burton JO, Hothi D, Korsheed S, Owen PJ, Lai KB and Li PK. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. *Clin J Am Soc Nephrol.* 2011;6(1):133-41. doi: 10.2215/CJN.04610510. PubMed PMID: 20876680; PMCID: PMC3022234. URL: <http://www.ncbi.nlm.nih.gov/pubmed/20876680>.
96. Lau WL, Savoj J, Nakata MB and Vaziri ND. Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins. *Clin Sci (Lond)*. 2018;132(5):509-522. doi: 10.1042/CS20171107. PubMed PMID: 29523750. URL: <https://www.ncbi.nlm.nih.gov/pubmed/29523750>.
97. Lai S, Molfino A, Testorio M, Perrotta AM, Currado A, Pintus G, Pietrucci D, Unida V, La Rocca D, Biocca S and Desideri A. Effect of Low-Protein Diet and Inulin on Microbiota and Clinical Parameters in Patients with Chronic Kidney Disease. *Nutrients.* 2019;11(12). Epub 2019/12/09. doi: 10.3390/nu11123006. PubMed PMID: 31818021. URL: <https://www.ncbi.nlm.nih.gov/pubmed/31818021>.
98. National Kidney Foundation (NKF). Plant-Based Diet and Kidney Health. *web* <https://www.kidney.org/atoz/content/plant-based>. 2019. doi. PubMed PMID.
99. Wang M, Chou J, Chang Y, Lau WL, Reddy U, Rhee CM, Chen J, Hao C and Kalantar-Zadeh K. The role of low protein diet in ameliorating proteinuria and deferring dialysis initiation: what is old and what is new. *Panminerva Med.* 2017;59(2):157-165. doi: 10.23736/S0031-0808.16.03264-X. PubMed PMID: 27759735. URL: <https://www.ncbi.nlm.nih.gov/pubmed/27759735>.
100. Hebert LA, Kusek JW, Greene T, Agodoa LY, Jones CA, Levey AS, Breyer JA, Faubert P, Rolin HA and Wang SR. Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. *Hypertension.* 1997;30(3 Pt

1):428-35. doi. PubMed PMID: 9314428. URL:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9314428

101. Kramer H, Jimenez EY, Brommage D, Vassalotti J, Montgomery E, Steiber A and Schofield M. Medical Nutrition Therapy for Patients with Non-Dialysis-Dependent Chronic Kidney Disease: Barriers and Solutions. *J Acad Nutr Diet*. 2018;118(10):1958-1965. doi:

10.1016/j.jand.2018.05.023. PubMed PMID: 30076072. URL:

<https://www.ncbi.nlm.nih.gov/pubmed/30076072>.

102. Kalantar-Zadeh K and Moore LW. Impact of Nutrition and Diet on COVID-19 Infection and Implications for Kidney Health and Kidney Disease Management. *J Ren Nutr*.

2020;30(3):179-181. doi: 10.1053/j.jrn.2020.03.006. PubMed PMID: 32291198; PMCID:

PMC7186539. URL: <https://www.ncbi.nlm.nih.gov/pubmed/32291198>.

103. Kelly JT, Campbell KL, Hoffmann T and Reidlinger DP. Patient Experiences of Dietary Management in Chronic Kidney Disease: A Focus Group Study. *J Ren Nutr*. 2018;28(6):393-402.

doi: 10.1053/j.jrn.2017.07.008. PubMed PMID: 29146140. URL:

<https://www.ncbi.nlm.nih.gov/pubmed/29146140>.

104. 1053 DoVAVD. CHRONIC KIDNEY DISEASE PREVENTION, EARLY RECOGNITION, AND MANAGEMENT. *Veterans Health Administration Transmittal Sheet*. 2020(Washington, DC 20420 March 17,

2020):[https://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=8737]. doi. PubMed PMID.

105. Kalantar-Zadeh K, Tortorici AR, Chen JL, Kamgar M, Lau WL, Moradi H, Rhee CM, Streja E and Kovesdy CP. Dietary restrictions in dialysis patients: is there anything left to eat? *Semin Dial*.

2015;28(2):159-68. doi: 10.1111/sdi.12348. PubMed PMID: 25649719; PMCID: PMC4385746.

URL: <http://www.ncbi.nlm.nih.gov/pubmed/25649719>.

106. Noori N, Kovesdy CP, Bross R, Lee M, Oreopoulos A, Benner D, Mehrotra R, Kopple JD and Kalantar-Zadeh K. Novel equations to estimate lean body mass in maintenance hemodialysis patients. *Am J Kidney Dis*. 2011;57(1):130-9. doi: 10.1053/j.ajkd.2010.10.003. PubMed PMID:

21184920; PMCID: 3026443. URL: <http://www.ncbi.nlm.nih.gov/pubmed/21184920>.

107. Noori N, Kopple JD, Kovesdy CP, Feroze U, Sim JJ, Murali SB, Luna A, Gomez M, Luna C, Bross R, Nissenson AR and Kalantar-Zadeh K. Mid-Arm Muscle Circumference and Quality of Life and Survival in Maintenance Hemodialysis Patients. *Clin J Am Soc Nephrol*. 2010 [in press][on line]. doi. PubMed PMID.

108. Kalantar-Zadeh K, Dunne E, Nixon K, Kahn K, Lee GH, Kleiner M and Luft FC. Near infra-red interactance for nutritional assessment of dialysis patients. *Nephrol Dial Transplant*.

1999;14(1):169-75. doi. PubMed PMID: 10052499. URL:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10052499.

109. Kalantar-Zadeh K, Block G, Kelly MP, Schroepfer C, Rodriguez RA and Humphreys MH. Near infra-red interactance for longitudinal assessment of nutrition in dialysis patients. *J Ren Nutr*. 2001;11(1):23-31. doi. PubMed PMID: 11172450. URL:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11172450.

110. Kalantar-Zadeh K, Kuwae N, Wu DY, Shantouf RS, Fouque D, Anker SD, Block G and Kopple JD. Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. *Am J Clin Nutr*. 2006;83(2):202-10. doi. PubMed PMID:

16469976. URL:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16469976

111. Kalantar-Zadeh K, Kopple JD, Block G and Humphreys MH. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. *Am J Kidney Dis*. 2001;38(6):1251-63. doi: 10.1053/ajkd.2001.29222. PubMed PMID: 11728958. URL: <http://www.ncbi.nlm.nih.gov/pubmed/11728958>.

112. Rambod M, Kovesdy CP and Kalantar-Zadeh K. Malnutrition-Inflammation Score for risk stratification of patients with CKD: is it the promised gold standard? *Nat Clin Pract Nephrol*. 2008;4(7):354-5. doi: 10.1038/ncpneph0834. PubMed PMID: 18523431. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18523431>.

113. Rambod M, Bross R, Zitterkoph J, Benner D, Pithia J, Colman S, Kovesdy CP, Kopple JD and Kalantar-Zadeh K. Association of Malnutrition-Inflammation Score with quality of life and mortality in hemodialysis patients: a 5-year prospective cohort study. *Am J Kidney Dis*. 2009;53(2):298-309. doi: 10.1053/j.ajkd.2008.09.018. PubMed PMID: 19070949. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19070949>.

114. Molnar MZ, Keszei A, Czira ME, Rudas A, Ujszaszi A, Haromszeki B, Kosa JP, Lakatos P, Sarvary E, Beko G, Fornadi K, Kiss I, Rempert A, Novak M, Kalantar-Zadeh K, Kovesdy CP and Mucsi I. Evaluation of the malnutrition-inflammation score in kidney transplant recipients. *Am J Kidney Dis*. 2010;56(1):102-11. doi: 10.1053/j.ajkd.2010.02.350. PubMed PMID: 20471737. URL: <http://www.ncbi.nlm.nih.gov/pubmed/20471737>.

115. Bross R, Chandramohan G, Kovesdy CP, Oreopoulos A, Noori N, Golden S, Benner D, Kopple JD and Kalantar-Zadeh K. Comparing Body Composition Assessment Tests in Long-term Hemodialysis Patients. *Am J Kidney Dis*. 2010. Epub 2010/03/30. doi: S0272-6386(10)00030-2 [pii]

10.1053/j.ajkd.2009.12.031. PubMed PMID: 20346558. URL:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20346558.

116. Heimbürger O, Qureshi AR, Blaner WS, Berglund L and Stenvinkel P. Hand-grip muscle strength, lean body mass, and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. *Am J Kidney Dis*. 2000;36(6):1213-25. doi: PubMed PMID: 11096047. URL: <http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=11096047>

<http://www.ajkd.org/cgi/content/full/36/6/1213>

<http://www.ajkd.org/cgi/content/abstract/36/6/1213>.

117. Kalantar-Zadeh K and Amin AN. Toward more accurate detection and risk stratification of chronic kidney disease. *JAMA*. 2012;307(18):1976-7. doi: 10.1001/jama.2012.4623. PubMed PMID: 22570467. URL: <http://www.ncbi.nlm.nih.gov/pubmed/22570467>.

118. Genoni A, Lo J, Lyons-Wall P and Devine A. Compliance, Palatability and Feasibility of PALEOLITHIC and Australian Guide to Healthy Eating Diets in Healthy Women: A 4-Week Dietary Intervention. *Nutrients*. 2016;8(8). doi: 10.3390/nu8080481. PubMed PMID: 27509519; PMCID: PMC4997394. URL: <https://www.ncbi.nlm.nih.gov/pubmed/27509519>.

119. Rocco MV, Dwyer JT, Larive B, Greene T, Cockram DB, Chumlea WC, Kusek JW, Leung J, Burrowes JD, McLeroy SL, Poole D, Uhlin L and Group HS. The effect of dialysis dose and membrane flux on nutritional parameters in hemodialysis patients: results of the HEMO Study. *Kidney Int*. 2004;65(6):2321-34. doi: 10.1111/j.1523-1755.2004.00647.x. PubMed PMID: 15149346. URL: <https://www.ncbi.nlm.nih.gov/pubmed/15149346>.

120. Weisbord SD, Fried LF, Arnold RM, Rotondi AJ, Fine MJ, Levenson DJ and Switzer GE. Development of a symptom assessment instrument for chronic hemodialysis patients: the Dialysis Symptom Index. *J Pain Symptom Manage*. 2004;27(3):226-40. doi. PubMed PMID: 15010101. URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15010101.
121. Atkinson MJ, Wishart PM, Wasil BI and Robinson JW. The Self-Perception and Relationships Tool (S-PRT): a novel approach to the measurement of subjective health-related quality of life. *Health Qual Life Outcomes*. 2004;2:36. doi. PubMed PMID: 15257754. URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15257754
122. Kalantar-Zadeh K, Kovesdy CP, Bross R, Benner D, Noori N, Murali SB, Block T, Norris J, Kopple JD and Block G. Design and development of a dialysis food frequency questionnaire. *J Ren Nutr*. 2011;21(3):257-62. doi: 10.1053/j.jrn.2010.05.013. PubMed PMID: 20833073; PMCID: 3047592. URL: <http://www.ncbi.nlm.nih.gov/pubmed/20833073>.
123. Sumida K, Molnar MZ, Potukuchi PK, Thomas F, Lu JL, Yamagata K, Kalantar-Zadeh K and Kovesdy CP. Constipation and risk of death and cardiovascular events. *Atherosclerosis*. 2019;281:114-120. doi: 10.1016/j.atherosclerosis.2018.12.021. PubMed PMID: 30658186; PMCID: PMC6399019. URL: <https://www.ncbi.nlm.nih.gov/pubmed/30658186>.
124. Sumida K, Molnar MZ, Potukuchi PK, Thomas F, Lu JL, Matsushita K, Yamagata K, Kalantar-Zadeh K and Kovesdy CP. Constipation and Incident CKD. *J Am Soc Nephrol*. 2017;28(4):1248-1258. doi: 10.1681/ASN.2016060656. PubMed PMID: 28122944; PMCID: PMC5373459. URL: <https://www.ncbi.nlm.nih.gov/pubmed/28122944>.
125. Kistler BM, Moore LW, Benner D, Biruete A, Boaz M, Brunori G, Chen J, Drechsler C, Guebre-Egziabher F, Hensley MK, Iseki K, Kovesdy CP, Kuhlmann MK, Saxena A, ter Wee P, Brown-Tortorici A, Garibotto G, Price SR, Wang AY-M and Kalantar-Zadeh K. The International Society of Renal Nutrition and Metabolism Commentary on the National Kidney Foundation and Academy of Nutrition and Dietetics KDOQI Clinical Practice Guideline for Nutrition in Chronic Kidney Disease. *J Ren Nutr*. 2020 [in press];30(4). doi. PubMed PMID.
126. Esmeijer K, Geleijnse JM, de Fijter JW, Kromhout D and Hoogeveen EK. Dietary protein intake and kidney function decline after myocardial infarction: the Alpha Omega Cohort. *Nephrol Dial Transplant*. 2019. doi: 10.1093/ndt/gfz015. PubMed PMID: 30768201. URL: <https://www.ncbi.nlm.nih.gov/pubmed/30768201>.
127. Jhee JH, Kee YK, Park S, Kim H, Park JT, Han SH, Kang SW and Yoo TH. High-protein diet with renal hyperfiltration is associated with rapid decline rate of renal function: a community-based prospective cohort study. *Nephrol Dial Transplant*. 2020;35(1):98-106. doi: 10.1093/ndt/gfz115. PubMed PMID: 31172186. URL: <https://www.ncbi.nlm.nih.gov/pubmed/31172186>.
128. Rosman JB, ter Wee PM, Meijer S, Piers-Becht TP, Sluiter WJ and Donker AJ. Prospective randomised trial of early dietary protein restriction in chronic renal failure. *Lancet*. 1984;2(8415):1291-6. doi. PubMed PMID: 6150320. URL: <http://www.ncbi.nlm.nih.gov/pubmed/6150320>.
129. Rosman JB, Langer K, Brandl M, Piers-Becht TP, van der Hem GK, ter Wee PM and Donker AJ. Protein-restricted diets in chronic renal failure: a four year follow-up shows limited indications. *Kidney Int Suppl*. 1989;27:S96-102. doi. PubMed PMID: 2636680. URL: <http://www.ncbi.nlm.nih.gov/pubmed/2636680>.
130. Ihle BU, Becker GJ, Whitworth JA, Charlwood RA and Kincaid-Smith PS. The effect of protein restriction on the progression of renal insufficiency. *N Engl J Med*. 1989;321(26):1773-7.

doi: 10.1056/NEJM198912283212601. PubMed PMID: 2512486. URL:

<http://www.ncbi.nlm.nih.gov/pubmed/2512486>.

131. Lindenau K, Abendroth K, Kokot F, Vetter K, Rehse C and Frohling PT. Therapeutic effect of keto acids on renal osteodystrophy. A prospective controlled study. *Nephron*.

1990;55(2):133-5. doi. PubMed PMID: 2132299. URL:

<http://www.ncbi.nlm.nih.gov/pubmed/2132299>.

132. Williams PS, Stevens ME, Fass G, Irons L and Bone JM. Failure of dietary protein and phosphate restriction to retard the rate of progression of chronic renal failure: a prospective, randomized, controlled trial. *Q J Med*. 1991;81(294):837-55. Epub 1991/10/01. doi. PubMed PMID: 1801057. URL:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1801057.

133. Locatelli F, Alberti D, Graziani G, Bucciatti G, Redaelli B and Giangrande A. Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. *Lancet*. 1991;337(8753):1299-304. Epub 1991/06/01. doi. PubMed PMID: 1674294. URL:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1674294.

134. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW and Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. *N Engl J Med*. 1994;330(13):877-84. Epub 1994/03/31. doi: 10.1056/NEJM199403313301301. PubMed PMID: 8114857. URL:

<http://www.ncbi.nlm.nih.gov/pubmed/8114857>.

135. Montes-Delgado R, Guerrero Riscos MA, Garcia-Luna PP, Martin Herrera C, Pereira Cunill JL, Garrido Vazquez M, Lopez Munoz I, Suarez Garcia MJ, Martin-Espejo JL, Soler Junco ML and Barbosa Martin F. [Treatment with low-protein diet and caloric supplements in patients with chronic kidney failure in predialysis. Comparative study]. *Rev Clin Esp*. 1998;198(9):580-6. Epub 1998/11/06. doi. PubMed PMID: 9803777. URL:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9803777.

136. Malvy D, Maingourd C, Pengloan J, Bagros P and Nivet H. Effects of severe protein restriction with ketoanalogues in advanced renal failure. *J Am Coll Nutr*. 1999;18(5):481-6. Epub 1999/10/08. doi. PubMed PMID: 10511331. URL:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10511331.

137. Teplan V, Schuck O, Knotek A, Hajny J, Horackova M, Skibova J and Maly J. Effects of low-protein diet supplemented with ketoacids and erythropoietin in chronic renal failure: a long-term metabolic study. *Ann Transplant*. 2001;6(1):47-53. doi. PubMed PMID: 11803607. URL:

<http://www.ncbi.nlm.nih.gov/pubmed/11803607>.

138. Prakash S, Pande DP, Sharma S, Sharma D, Bal CS and Kulkarni H. Randomized, double-blind, placebo-controlled trial to evaluate efficacy of ketodiet in predialytic chronic renal failure. *J Ren Nutr*. 2004;14(2):89-96. Epub 2004/04/03. doi: S1051227604000093 [pii]. PubMed PMID: 15060873. URL:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15060873.

139. Brunori G, Viola BF, Parrinello G, De Biase V, Como G, Franco V, Garibotto G, Zubani R and Cancarini GC. Efficacy and safety of a very-low-protein diet when postponing dialysis in the elderly: a prospective randomized multicenter controlled study. *Am J Kidney Dis*.

- 2007;49(5):569-80. doi: 10.1053/j.ajkd.2007.02.278. PubMed PMID: 17472838. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17472838>.
140. Mircescu G, Garneata L, Stancu SH and Capusa C. Effects of a supplemented hypoproteic diet in chronic kidney disease. *J Ren Nutr*. 2007;17(3):179-88. Epub 2007/04/28. doi: S1051-2276(06)00298-6 [pii]
- 10.1053/j.jrn.2006.12.012. PubMed PMID: 17462550. URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17462550.
141. Cianciaruso B, Pota A, Pisani A, Torraca S, Anecchini R, Lombardi P, Capuano A, Nazzaro P, Bellizzi V and Sabbatini M. Metabolic effects of two low protein diets in chronic kidney disease stage 4-5--a randomized controlled trial. *Nephrol Dial Transplant*. 2008;23(2):636-44. doi: 10.1093/ndt/gfm576. PubMed PMID: 17981885. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17981885>.
142. Di Iorio BR, Cucciniello E, Martino R, Frallicciardi A, Tortoriello R and Struzziero G. [Acute and persistent antiproteinuric effect of a low-protein diet in chronic kidney disease]. *G Ital Nefrol*. 2009;26(5):608-15. doi. PubMed PMID: 19802806. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19802806>.
143. Jiang N, Qian J, Sun W, Lin A, Cao L, Wang Q, Ni Z, Wan Y, Linholm B, Axelsson J and Yao Q. Better preservation of residual renal function in peritoneal dialysis patients treated with a low-protein diet supplemented with keto acids: a prospective, randomized trial. *Nephrol Dial Transplant*. 2009;24(8):2551-8. Epub 2009/03/05. doi: 10.1093/ndt/gfp085. PubMed PMID: 19258386. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19258386>.
144. Jiang N, Qian J, Lin A, Fang W, Zhang W, Cao L, Wang Q, Ni Z and Yao Q. Low-protein diet supplemented with keto acids is associated with suppression of small-solute peritoneal transport rate in peritoneal dialysis patients. *International journal of nephrology*. 2011;2011:542704. doi: 10.4061/2011/542704. PubMed PMID: 21747999; PMCID: PMC3124873. URL: <http://www.ncbi.nlm.nih.gov/pubmed/21747999>.
145. Garneata L, Stancu A, Dragomir D, Stefan G and Mircescu G. Ketoanalogue-Supplemented Vegetarian Very Low-Protein Diet and CKD Progression. *J Am Soc Nephrol*. 2016;27(7):2164-76. doi: 10.1681/ASN.2015040369. PubMed PMID: 26823552; PMCID: PMC4926970. URL: <https://www.ncbi.nlm.nih.gov/pubmed/26823552>.

Tables

Table 1. Selected studies of high-protein and kidney function

Study (Year)	Cohort, [N] (Country)	Duration of follow up	Findings
Esmeijer ¹²⁶ (2020)	Alpha Omega Cohort [2,255] (Netherlands)	41 mo	↑ DPI 0.1 g/kg/day associated with ↑ eGFR decline of -0.12 ml/min/year
Jhee ¹²⁷ (2020)	South Korea [9,226]	14 yrs	3.5-fold ↑ risk of hyperfiltration. 1.3-fold ↑ faster decline
Malhotra ²³ (2018)	Jackson Heart (USA) [5,301]	8 yrs	↑ DPI density associated with ↑ eGFR decline
Farhadnejad ²³ (2018)	Healthy Iranian adults [1,797]	6.1 yrs	48% ↑ risk of incident CKD in high DPI

Table 2. LPD controlled trials with greater than 30 participants in each study.²²

Study (Year)	Participants	Diet (g/kg/day)	Duration of follow up	Results
Rosman (1984) ^{128, 129}	247 CKD 3-5 pts	0.90-0.95 vs. 0.70-0.80 vs. unrestricted	4 yrs	Significant CKD slowing in LPD in male pts.
Ihle (1989) ¹³⁰	72 CKD 4-5 pts	LPD (0.6) vs. higher DPI (0.8)	18 mo	Loss of GFR in control vs LPD (p<0.05). Wt loss
Lindenau (1990) ¹³¹	40 CKD 5 pts	LPD vs sVLPD (0.4) w KA	12 mo	Decreased phos. with sVLPD and improved bone health
Williams (1991) ¹³²	95 CKD 4-5	LPD (0.7) vs 1.02-1.14	18 mo	No differences, minor Wt loss
Locatelli (1991) ¹³³	456 CKD 3-4	0.78 vs 0.9	2 yrs	Trend for difference in renal outcomes (p = 0.059).
MDRD Klahr (1994) ¹³⁴	585 CKD 3-4	1.3 vs. 0.6	27 mo	No difference in GFR decline at 3 years.
Montes-Delgado (1998) ¹³⁵	33 CKD 3-5	LPD vs suppl.LPD	6 mo	Slower eGFR decline with supplements
Malvy (1999) ¹³⁶	50 CKD 4-5	sVLPD (0.3) KA vs. LPD (0.65)	3 yrs	Decreased SUN lean body mass and fat in sVLPD
Teplan (2001) ¹³⁷	105 CKD 3b-4	LPD w vs w/o KA	3 yrs	Slower CKD progression
Prakash (2004) ¹³⁸	34 CKD 3b-4	0.6 vs. 0.3 w KA	9 mo	Faster decline in LPD
Brunori (2007) ¹³⁹	56 >70 yrs old CKD 5	sVLPD (0.30) w KA vs dialysis	27 mo	Similar survival but more hospitalizations in dialysis
Mircescu (2007) ¹⁴⁰	53 CKD 4-5	sVLPD (0.3) vegan w KA vs LPD	48 wks	Less dialysis initiation in sVLPD
Cianciaruso (2008) ¹⁴¹	423 CKD 4-5	0.55 vs 0.80	18 mo	Reduced urinary urea, Na, phos
Di Iorio (2009) ¹⁴²	32 CKD w proteinuria	VLPD vs. LPD	6 mo	58% greater reduction in proteinuria
Jiang (2009 & 2011) ^{143, 144}	60 PD w RKF	LPD vs sLPD w KA vs HPD	12 mo	RKF decreased in the LPD and HPD.
Garneata (2016) ¹⁴⁵	207 CKD 4-5	LPD (0.6) vs. sVLPD w KA	15 mo	Less dialysis initiation

Abbreviations: Pts: patients, yrs: years, mo: months, Et: weight, phos.: phosphorus, sVLPD: supplemented very low protein diet,

Table 3. Benefits and challenges of LPD with >50% plant-based protein sources

Benefits of LPD with >50% plant sources	Potential Challenges of LPD
<ul style="list-style-type: none">• Lowering intra-glomerular pressure• Synergistic effect with RAASi & SGLT2i• Controlling uremia and delaying dialysis• Preventing cardiovascular harms of meat• Less absorbable phosphorus• Lowering acid-load with less acidogenicity• High dietary fiber enhancing GI motility• Favorable changes in microbiome• less TMAO leading to less kidney fibrosis• Less inflammation and oxidative stress	<ul style="list-style-type: none">• Risk of protein-energy wasting (PEW)• Inadequate essential amino acids• Undermining obesity management• High glycemic index• High potassium load and hyperkalemia• Low palatability and adherence• Inadequate fish intake if vegan

Table 4. Comparing Low Protein Diet (LPD) >50% plant-based protein sources. Known as PLADO, versus standard diet, based on 2,400 Cal/day in an 80-kg person

Protein Metric	Standard diet	LPD >50% plant-based sources (PLADO)
Proportion of plant-based protein, %	20-30%	50-70%*
Total protein per kg IBW, g/kg/day	>0.8, usually 1.2-1.4	0.6-0.8
Total protein intake, g/day	96 to 112 g	48 to 64 g
Protein density, g/100Cal	4.4-5.1	2.2-2.9
Proportion of energy from protein,%	16-19%	8-11%
Total plant-based protein, g/day	24-34	24-45
Total animal-based protein, g/day	68-83	14-32 (or none*)

*up to 100% vegan is allowed based on patient choice

Table 5. Overview of the recommended ambulatory visits and tests under the PLADO regimen (*these items are more relevant to sophisticated centers or under research protocols)

	Timeline of for PLADO therapy visits	"Run-in" period			Year 1 (quarterly)			Years 2+ (semi-annual)				Needed time
		0	1	3	6	9	12	18	24	30	36	
	PALDO Months											
	History and physical examination with updates on clinical and dietary status	X	x	x	x	x	X	x	x	x	x	10-20 min
Lab tests	Routine lab panel: CMP/LFT, anemia, MBD, A1c	X		x	x	x	X	x	x	x	x	<10 min
	Spot urine, urinalysis, protein, albumin, creatinine	X		x	x	x	X	x	x	x	x	<5 min
	24 hr urine: Nitrogen, Na, K, creatinine, alb, prot.	X		x	x	x	X	x	x	x	x	Collected at home
	eGFR assessment and creatinine & urea clearance	X		x	x	x	X	x	x	x	x	
Dietitian visit	Dietary education for LPD >50% plant based	X	x	x	x	x	X	x	x	x	X	10-20 min
	Dietary assessment, 3-day diet diary with interview	X	x	x	x	x	X	x	x	x	X	10-20 min
	Anthropometry: triceps and biceps skinfolds, mid-arm circumference*	X		x	x	x	X	x	x	x	X	2-4 min
	Body fat estimation*	X		x	x	x	X	x	x	x	X	1-2 min
	Malnutrition-inflammation score*	X		x	x	x	X	x	x	x	x	2-5 min
	Handgrip strength test*	X		x	x	x	X	x	x	x	x	1-2 min
	Phone calls to reinforce PLADO education, adherence, and meal preparation	x	x	x	x	x	X	x	x	x	x	10-30 min
Questionnaires	Diet palatability and appetite questionnaire	x	x	x	X	x	X	x	x	x	x	15-30 min
	Food Frequency Questionnaire *	x			x		X	x	x	x	x	15-30 min
	Quality of life: KDQOL™ including SF36 quest.*	x		x	x	x	X	x	x	x	x	10-15 min
	Uremic symptoms questionnaire	x		x	x	x	X	x	x	x	x	10-15 min
	Self-Perception and Relationship Questionnaire*	x		x	x	x	X	x	x	x	x	10-15 min

Abbreviations: RD: Registered dietitian, CMP: comprehensive metabolic panel, LFT: liver function tests, MBD: Mineral and bone disease markers, Na: sodium, K: potassium, Na, K, creatinine, alb: albumin, prot.: protein, KDQOL: Kidney disease quality of life, SF36: Short Form with 36 items of quality of life,

Figures

Figure 1. Effects of a plant-dominant low-protein diet on afferent arteriole contraction leading to reduced intra-glomerular pressure and nephron longevity (adapted from Kalantar-Zadeh and Fouque, *N Engl J Med* 2017).²²




Figure 2. Meta-analysis of the randomized controlled trials with low protein diet suggesting efficacy of diet in lowering the risk of kidney failure. This meta-analysis includes 6 (out of 16) randomized control trials of low protein diet (adapted from Rhee et al, *J Cachexia Sarcopenia Muscle* 2018).²⁶




Figure 3. Overview of the plant-dominant low-protein diet (PLADO) for nutritional management of CKD, based on a total dietary intake of 0.6-0.8 g/kg/day with >50% plant-based sources, preferentially unprocessed foods, relatively low dietary sodium intake <3 g/day (but the patient can target to avoid >4 g/day if no edema with well controlled hypertension), higher dietary fiber of at least 25-30 g/day, and adequate dietary energy intake of 30-35 Cal/kg/day. Weight is based on the ideal body weight. Note that serum B12 should be monitored after 3 years of vegan dieting.





Figure 4. An algorithm and steps for the approach to the nutritional management of patients with CKD. Note that in addition to direct dietary assessments, periodic 24-hour urine collections should be used to estimate dietary protein, sodium and potassium intakes in order to assess adherence to dietary recommendations (adapted from the Supplementary-Appendix-Fig. S4. Under Kalantar-Zadeh and Fouque, *N Engl J Med* 2017)²².



* Comprehensive metabolic and glycemic panels include electrolytes, SUN, creatinine, glucose, hemoglobin A1c, liver function tests, and the lipid panel.

[†] The full equation is: $DPI = 6:25 \times UUN + 0:03 \times IBW$ [†] Add the amount of daily proteinuria in grams if proteinuria > 5 g/d. Calculate the *creatinine index* (24-hr urine creatinine divided by actual weight or IBW if obese) and compare it to the expected value of 1-1.5 g/kg/d for women and 1.5-2 g/kg/day for men.

[‡] Dietary supplements can be added to provide additional sources of energy and/or protein including – but not limited to – CKD specific supplements, essential amino-acids, or keto-analogues (ketoacids) of amino-acids.

[¶] To ensure adequate DEI of at least 30-35 Cal/kg/d, higher fat intake can be considered, e.g. non-saturated fats, omega 3-rich flaxseed, canola, and olive oil.

^{‡‡} If worsening uremic signs and symptoms occur, DPI < 0.6 g/kg/d with supplements can be considered.

Abbreviations: BMI: body mass index, CKD: chronic kidney disease, d: day, DEI: dietary energy intake, DPI: dietary protein intake; eGFR: estimated glomerular filtration rate, GI: gastrointestinal, HBV: high biologic value, IBW: ideal body weight, ISRNM: International Society of Renal Nutrition and Metabolism,

K: potassium; MIS: malnutrition–inflammation score; Na: sodium; Phos.: phosphorus; PTH: parathyroid hormone, PEW: protein energy wasting, SGA: subjective global assessment, SUN: serum urea nitrogen, UUN: urine urea nitrogen.

This page is left blank